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CHAPTER I 
GENERAL INTRODUCTION 

CHAPTER 1: INTRODUCTION 
1.1 HISTORY 
Only a few decennia ago the exact cause of infectious jaundice was still unknown (188). 
The disease was thought to be transmitted either orally or by the airborne route. 
However, in 1883 an epidemic of jaundice occurred in Bremen among shipyard workers 
who were vaccinated for small pox (87). This has been considered as the first description 
of classical hepatitis В transmission. 
During the second world war it was demonstrated that certain forms of hepatitis had a 
viral origin. Subsequent epidemiological studies indicated that there were at least two 
forms of "infectious hepatitis" (188): One form, later identified as hepatitis A, has a short 
incubation period and is transmitted via a faecc-oral route. The infectious agent, the 
hepatitis A virus or HAV, is a picorna virus (enterovirus type 72), containing a single 
stranded RNA genome with a length of approximately 7500 nucleotides. This virus has no 
envelope proteins (171). 
The second form, later known as hepatitis B, has a longer incubation period and is 
transmitted parenterally. In contrast to HAV, the hepatitis В virus (HBV) is a DNA virus 
which contains envelope proteins (26,160). 
Other hepatotropic viruses, known so far to cause hepatitis are: 
- the hepatitis С virus (HCV, discovered in 1989 and formerly known as post­
transfusion non-Α non-B (NANB) hepatitis virus). This virus has approximately the 
same transmission routes as HBV (see section 1.4). Its genome consists of a single 
stranded RNA molecule with a length greater than 10,000 bases (29,171). 
- the hepatitis β virus (HDV), first described in 1980 (13). The viral genome consists of 
an RNA molecule (circular, 1,700 bases), packed in δ-antigen. This core is encoated 
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by an envelope of HBsAg (171). Infection with this virus is only possible either as a 
co-infection with hepatitis В virus or as a super-infection in chronic hepatitis В 
patients. 
- the hepatitis E virus (HEV), which is the cause of the epidemic form of non-Α non-B 
hepatitis (171). The hepatitis E virus is spread by contaminated water or food (un­
hygienic circumstances). 
1.2 STRUCTURE OF THE HEPATITIS В VIRUS 
In 1965, Blumberg and co-workers discovered the 'Australia-antigen' in the blood of an 
Australian aboriginal (6,11,12). The subsequent demonstration by Prince in 1968 that this 
antigen was associated with type В hepatitis (131), followed by the detection of viral-like 
particles by Dane in serum of hepatitis B-infected patients (Dane-particles, 32), initiated 
an enormous amount of research that lead to the current knowledge of this virus. 
The hepatitis В virus is a member of the class of hepatitis associated DNA (hepadna) 
viruses (135). Other members of this group include: 
ground squirrel hepatitis virus (GSHV,135) 
tree squirrel hepatitis virus (TSHV.46) 
woodchuck hepatitis virus (WHV.135) 
Pekin duck hepatitis virus (DHBV, 168) 
heron hepatitis virus (152) 
Hepadna-viruses share many similarities in overall structure, genomic organization and 
replication cycle (26,31,160). They display a strong hepatotropism with their own host 
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Dane particle 
42 nm 
Virus envelope 
(HbsAg) 
Virus core 
(HbcAg, HbeAg) 
Virus DNA 
(2 0i10*daltons) 
HbsAg particle 
specificity. Only humans, 
chimpanzees and gibbons 
are known so far to be sus­
ceptible to human hepatitis 
В vims infection. Viral re­
plication takes place pre­
dominantly in the liver al­
though viral antigens and 
DNA can be demonstrated 
in other tissues as well 
(15,179). 
Figure 1.1 shows the three 
hepatitis В related struc­
tures that can be found in 
the serum of hepatitis В in­
fected persons. The com­
plete virion or Dane par­
ticle has a diameter of 42 
nm and is composed of a 
27 nm core, encoated by a 
host-cell derived lipid bi-
layer which contains the 
hepatitis В surface antigen 
(HBsAg). The core con­
tains, depending on the 
stage of its maturity, a pre-
genomic RNA molecule or a circular, incompletely double-stranded DNA molecule of 
3,200 bases (section 1.3.1), together with a DNA bound protein, an RNA-dependent 
DNA-polymerase and about 180 copies of the hepatitis В core antigen (HBcAg). The core 
HbsAg filament 
100-700 nm 
Figure 1.1 Hepatitis В related structures. Infectious virions 
(Dane particles) and spherical and filamentous aggregates of 
HBsAg are found in serum of infected persons. 
From 'Virology, a Scope publication', The Upjohn Company, 
1982. Published with Und permission of Dr. Rapp. the 
Upjohn Company. 
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has an isocahedral arrangement and is stabilized by intermolecular cross-linking of at least 
two of the four HBcAg cysteine residues. Cross-linking between HBcAg and HBsAg 
might also add to the stability of the virion (16,108, 109,184). HBcAg might also be 
found on the surface of circulating Dane particles in patients with hepatitis В virus 
infection without evidence of anti-HBc formation (105). 
Besides the infectious virions, two other infection-related structures are present in the 
serum of infected persons. These are spherical particles with a diameter of 22 nm and 
filamentous particles with lengths of up to 400 nm. Both these structures are composed of 
only HBsAg and phospholipids and may be present in large quantities (1013 particles/ml, 
which is approximately 1000-fold as much as the number of Dane particles per ml). 
1.3 MOLECULAR BIOLOGY OF THE HEPATITIS В VIRUS 
1.3.1 THE VIRAL GENOME 
The hepatitis В virus is a DNA virus with a very unusual genomic structure and 
replication cycle (103,160). It contains a nicked circular, partially double-stranded DNA 
molecule (figure 1.2). The complete circular strand has a length of approximately 
3,200 bases. This long strand is called the L or minus strand and contains at least four 
open reading frames. The incomplete strand (Sfhort) or plus strand) has heterogenous 3'-
ends (resulting in a length of 50-100% of the L-strand). 
There is only one EcoRl restriction cleavage site in the genome that has been designated 
as site 0 (160). At site 1820 the L-strand is nicked. Despite this nick the partially double 
stranded molecule remains circular. This is due to complementary base pairing of about 
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200 overlapping bases which are flanked by two 'direct repeats' of 11 bp (DR1 and 
DR2, 160). A protein is covalently bound to the S'-end of the L-strand, probably serving 
as a primer for RNA synthesis (14,26). 
OJkb RNA 
Figure 1.2 Physical map of the hepatitis В virus genome. Open reading frames C, Ρ, X 
and S are indicated, as well as the known transcripts. Modified from Michel and Tiollais, 
Hepatology 7; 61S-63S (1987), with permission 
1.3.2 HBV TRANSCRIPTS AND PROMOTERS 
HBV DNA contains four overlapping open reading frames (ORF's) called S, C, X and Ρ 
as designated in figure 1.2. Recently a fifth and a sixth ORF have been postulated 
(69,103), although the significance of these ORF's has not yet been elucidated. All these 
ORF's are localized on the L-strand, which is read 1.5 times. Subtypes of HBV have 
deletions or insertions of multiples of three nucleotides so that the ORF's of subtypes 
remain in frame. 
Transcription of the S-ORF, containing the information necessary for production of 
HBsAg, is regulated, by the alternative S-promoter (no TATA sequence) and a preSl 
promoter which has the usual TATA-structure (154,160). The S-promoter produces a 
transcript of 2.1 Kb, one of the two major viral RNA's which are found in liver in which 
active viral replication takes place. As the 2.1 Kb RNA has micro-heterogenous 5'-ends, 
it is able to code for two polypeptides, the middle HBsAg and the major HBsAg (see 
section 1.3.4.4). The preSl-promoter regulates the production of the large HBsAg via a 
2.4 Kb transcript which is always present in very low amounts. 
The C-promoter. located upstream from the C-ORF, produces the other abundant RNA 
which is 3.5 Kb in length. This RNA is also micro-heterogenous at its 5'-end and codes 
for the core antigen (HBcAg), the e-antigen (HBeAg, both encoded for by the C-ORF), 
the RNA-dependent DNA polymerase (encoded for by the P-ORF) and the DNA bound 
protein. This transcript, which is greater than genome length, also functions as the 
pregenomic RNA. The 2.1 Kb and the 3.5 Kb transcripts are both terminated at the same 
poly-adenylation site on the genome. 
The last known promoter is the X-ORF promoter. This promoter is far less active than 
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the S and the С promoter. Only recently an X-specific transcript of 0.7 Kb has been iden­
tified in infected liver. This transcript is not poly-adenylated and is present in very low 
amounts in the infected cell Qess than 1% of total viral RNA, 69). 
1.3.3 TRANSLATION PRODUCTS OF THE VARIOUS ORF's 
1.3.3.1 C-ORF 
The C-ORF is composed of a C-gene and a pre-C region. The C-gene encodes the 
hepatitis В core antigen (HBcAg), a protein of 183 amino acids with a molecular weight 
of 22 kilodaltons (KD) which has protein kinase activity (68,140,141). The carboxy-
terminal part of this protein is very rich in arginine, proline and serine, amino acids that 
are often found in DNA-binding proteins (e.g. protamine). This part of HBcAg (together 
with another DNA-binding sequence, 41) is responsible for binding to the viral 
pregenomic RNA and/or DNA leading to the formation of a stable core particle (96). 
As discussed in section 1.3.2, due to micro-heterogeneity at the 5*-end of the 3.5 Kb 
transcript, the translation product of the C-ORF can be preceded by the 29 amino acids 
long pre-C region (117). The resulting pre-core antigen is directed to the endoplasmatic 
reticulum by an N-terminal signal sequence of 19 amino acids and is transported to the 
Golgi-apparatus (118). The C- and N terminal sequences of the pre-core antigen may be 
cleaved there to yield the HBeAg (hepatitis В early antigen, 50) which is subsequently 
secreted by the hepatocytes. HBeAg has heterogeneous carboxy-terminal ends, resulting 
in molecular weights ranging from 17 to 20 Kd. 
The function of HBeAg is so far not known. This protein is not required for viral 
replication (24,145). Nevertheless it has been postulated that HBeAg has evolved to 
enable efficient transmission of the virus, especially from mother to child: maternal 
HBeAg from a HBeAg positive carrier mother crosses the placental barrier. As immuno-
cytes of the foetus are exposed to HBeAg in utero, an immunotolerance towards the virus 
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will be created, resulting in persistence of viral replication and the chronic carrier state 
(62). 
Since the HBV reverse transcriptase lacks the proof-reading ability of other DNA 
polymerases, the HBV genome is prone to mutations. Recently it has been established that 
mutations often occur in the preC/C-ORF and that they might be of clinical importance: it 
has recently been suggested that preC mutations are involved in the conversion to chronic 
hepatitis В (42), eventually accompanied by fulminant liver failure (see 1.5). 
1.3.3.2 P-ORF 
The P-ORF spans about 2,500 nucleotides (160). Its translation product is a histidine-rich 
protein with a Mw of 90 kD, bearing a striking resemblance to known retroviral RNA-
dependent DNA-polymerases or reverse transcriptase (136). The N-terminal region of the 
P-ORF in duck hepatitis В virus probably also codes for the protein which is covalently 
linked to the S'-end of the L-DNA strand. This protein is thought to serve as a primer for 
RNA synthesis (5,14). 
1.3.3.3 X-ORF 
An X-gene encoded protein of 17 Kd has been found in COS-cells (an African green 
monkey kidney cell line), transfected with an X-gene containing plasmid (149). An­
tibodies, directed against the X-polypeptide have been demonstrated in sera of patients 
with chronic active hepatitis В (САН, 81). It has been suggested that the presence of anti-
HBx antibodies in serum is correlated with the severity of the disease (57). 
The X-translation product has also been shown to have a trans-activating capacity for the 
transcription of various viral and cellular genes (146) and may therefore play a role in 
malignant transformation of the infected hepatocyte, leading to the development of hepato­
cellular carcinoma (see section 1.6). There is till now no known function of HBxAg 
regarding the viral life cycle. HBxAg-deficient HBV mutants as well as wild-type virus 
are capable of infecting liver-derived cell lines (10). 
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1.3.3.4 S-ORF 
The S gene is, like the C-gene, preceded by preSl and preS2-regions (figure 1.3). The 
translation product of the S-gene is the small hepatitis В surface antigen (HBsAg). The 
middle HBsAg contains an additional N-terminal 53 amino acids, encoded by the preS2 
region. When the preSl region is co-translated, the large HBsAg is formed with an 
additional N-terminal extension of 108-119 amino acids (depending on the subtype). Small 
HBsAg occurs in a non-glycosylated form (p24) and a glycosylated form (gp27, glyco-
sylation site at Asnl46). Middle HBsAg always has one or two glycan groups attached 
(gp33 and gp36). Large HBsAg (p39) may contain one glycan group (gp42). 
preS region S region 
| preSl preS2 \ I 
S-ORF I [. — ^ ^ ^ — 
119 aa 55 aa 226 aa S-gene 
Figure 1.3 Structure of the S-ORF and its translation products. Circles represent glycosylation 
sites on the translation products. 
Figure 1.4 Hypothetical structure and arrangement of HBsAg (from Peterson, D.h., BioEssays 
1987;6:258-262, with permission). 
The composition of surface antigens, present in the viral particle, differs from that in the 
spherical HBsAg 22 nm particles and the filamentous particles. Nevertheless, small 
HBsAg is the major component of viral envelope protein in all three structures. It is 
therefore also called major HBsAg. The spherical particles are composed of small HBsAg 
and very small amounts of middle HBsAg ( < 1 %) without detectable large HBsAg. The 
filamentous particles consist of approximately 5% middle HBsAg and <1% large 
HBsAg, while the envelope of the viral particle contains up to 10% middle HBsAg and 
1-2% large HBsAg. It is interesting to note that mutations in the S-ORF mostly occur in 
the preS2-region. This finding suggests that the preS2 sequences are probably not so 
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important for viral infection and assembly as the preSl and S-sequences are (33,121,136, 
160). 
A 22 nm HBsAg particle contains 100-120 protein molecules, extensively cross-linked by 
disulfide-bonds (59). Physical and chemical studies revealed that small HBsAg consists of 
three hydrophobic domains, each traversing the lipid bilayer twice, separated by two 
hydrophilic domains. The lipid-bound domains which are in the alpha-helical form, make 
up approximately 50% of HBsAg. The amino- and carboxyl termini of HBsAg as well as 
the hydrophilic preS sequences are located exterior of the particle. Figure 1.4 shows a 
hypothetical model for the arrangement of HBsAg in particles (39,40,121). 
Five antigenic determinants on the hepatitis В surface antigen (HBsAg) are known leading 
to a number of subtypes of HBV (121). The 'a' determinant is shared by all subtypes, 
while 'd','r','w' and 'y' are npt. Any combination between 'a' and two of the variable 
determinants may occur. The 'a'-determinant is generally assumed to be the chief 
antigenic site and is comprised of a hydrophilic domain, located in amino acid residues 
119-145 of the small HBsAg (160). As already mentioned, the subtypes differ from each 
other mostly in their preS2 regions. The S-gene is relatively conserved. 
1.3.4 REGULATION OF TRANSCRIPTION 
The regulation of transcription of the HBV genes is very complex (144). Figure 1.5 
shows a schematic representation of the known transcription-regulating elements on the 
viral genome. The S-promoter, partially resembling the SV-40 late promoter, is under the 
influence of several positive and negative elements (99). A hepatocyte nuclear factor 
binding site (HNF-1 BS) is present 200 bp upstream of the S-promoter and acts as a cis-
repressing element on the enhancer I in some cell lines and as a cis-activating element in 
others, giving rise to tissue specificity (148,187). Trans-activating factors, such as the 
ïepatiüs Β χ antigen (HBxAg) also determine the activity of the S-promoter (142,166) 
while two enhancers, enhancer I (ENI) and the liver specific enhancer Π (EMIT) play a 
-egulatory role on the activity of the C- and the S-promoter as well (25,55,174,178, 
182,186). 
HNF1-BS P r e S R E 
GRE 
EN I 
EN II 
Figure 1.5 Regulatory elements on 
the HBV genome 
Cp C-promoter 
preSlp preSI-promoter 
Sp S-promoter 
Xp X-promoter 
ENI enhancer element I; 
upregulates especially 
Xp and Cp 
ENII enhancer element II; 
upregulates especially Sp 
HNF1-BS hepatocyte nuclear fac­
tor binding site 1; bin­
ding ofHNFI to this se­
quence stimulates ENI 
GRE glucocortlcold-responsi-
ve element; binding of 
glucocorticoids to this 
sequence stimulates ENI 
preS RE preSl promoter repres­
sing element; this se­
quence inhibits, after 
transcription, the activity 
ofpreSIp 
ENI and ΕΝΠ activate viral replication and up-regulate viral gene expression in liver 
cells. A DNA sequence including the S-promoter down-regulates the preSI-promoter (18) 
while preSl RNA down-regulates the translation of preS2 and S sequences (95). ENI is 
induced by the action of glucocorticoids on a glucocorticoid-responsive element on the 
viral DNA (45,63,165). Section 1.10 of this thesis gives a more comprehensive survey on 
these factors with regard to tissue specificity. 
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1.3.5 VIRAL REPLICATION 
The infection and replication cycle of HBV are schematically depicted in figure 1.6. They 
involve the following steps (see also figure 1.6): 
1) In the initial step of infection, the viral particle is thought to bind to a cellular 
receptor via the surface protein (HBsAg). 
2) Following binding, the virus is translocated into the cell. The exact mechanism of 
binding and penetration is not yet known. One possible mechanism is that the viral 
core is released into the cytoplasm after fusion of viral and cellular membranes. 
Alternatively, virions are endocytosed and their cores are liberated by a membrane 
fusion event between the viral envelope and endosomal membranes. 
3,4) The naked core is translocated to the nucleus where the viral DNA is uncoated. 
5) The partial (+)-strand is completed by the viral DNA-polymerase to yield the 
covalently closed circular form (cccDNA). 
6) By utilizing host cell RNA polymerase Π, the several viral RNA's (pregenomic 
RNA and messenger RNA's) are transcribed from the cccDNA and transported to 
the cytoplasm (see section 1.3.2). 
In the cytoplasm the viral antigens are synthesized. The core antigen, which has 
nucleic acid binding capacities (section 1.3.4), selectively encapsidates the 
pregenomic RNA and forms an immature core particle, containing the newly 
produced RNA-dependent DNA polymerase and a protein, linked to the 5'-region 
of DR1. This encapsidation reaction is highly specific; neither non-viral RNA's 
nor subgenomic RNA's are encapsidated (43,61). 
7) Using the pregenomic RNA as a template and the DRl-linked protein as a primer, 
viral DNA is synthesized with simultaneous breakdown of pregenomic RNA by an 
RNase-H like activity of the reverse transcriptase. This process results in a range 
13 
of different length RNA-DNA hybrids which can be detected by Southern blotting 
and hybridization techniques. 
8) When the L(-)strand is completed, an RNA fragment containing the DR1 sequence 
remains protected from degradation. This fragment is translocated to the 
complementary DR2 region where it serves as a primer for subsequent synthesis of 
the S(+)- strand (figure 1.6). 
9) When the appropriate conditions are present for efficient action of the various viral 
promoters / enhancers (section 1.10), surface antigens are produced and directed 
to the plasma membrane via the endoplasmatic reticulum and Golgi-apparatus 
(181). There they are, either or not glycosylated, integrated in the plasma 
membrane. By the interactions of the immature core particles (probably via the 
hydrophobic preC peptide) with the surface antigen, contained in the cellular 
plasma membrane, complete virus particles are assembled and secreted. This 
process might involve exocytosis or reversed pinocytosis. 
Figure 1.6 Proposed viral life cycle. 
Details are discussed in the text. 
1) Binding to a receptor, 2) Fusion of viral 
and cellular membrane; 3) Entry of the 
viral core in the cell; 4) Uncoating of viral 
DNA; 5) Transport to the nucleus; 6) 
Transcription of messenger RNA 's (Sr) and 
pregenomic RNA (Pr) and translation of 
messenger RNA 's to yield the polymerase 
(P), HBcAg (C) and HBsAg (S). These 
steps are followed by core formation by 
complexing of P, C, Pr and a DNA-linked 
protein. Cores are probably secreted from 
the cell by budding from HBsAg rich caps 
In the membrane. 
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FREGENOMIC RNA 
¿ ΛΑΑΑΑΑ -£*\ 
I SYNTHESIS M-) STRAND VIA REVERSE TRANSCRIPTION USING A PROTEIN LINKED TO THE DR1 5'REGION AS PRIMER WITH SIMULTANEOUS BREAKDOWN OF PREGENOME RNA 
TRANSLOCATION DR I CONTAINING RNA 
Д/\А 
1 (PARTIALI SYNTHESIS S< + ) STRAND DNA I SING TRANSLOCATED RNA AS PRIMER 
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1.4 SOME EPIDEMIOLOGIC ASPECTS OF 
HEPATmS В VIRUS INFECTION 
According to estimations, there are more than 200 million HBsAg carriers, distributed 
worldwide (151,156,188). However, the different subtypes of HBsAg are not equally 
distributed in the various endemic regions. The 'ayw' subtype is predominantly found in 
northern and western Africa, the eastern Mediterranean and in the Indian subcontinent. 
The 'adw* subtype is especially distributed in northern Europe, the United States and 
Australia, while in the far east and the Pacific, the 'adr' subtype predominates. 
Even within one subtype, variations can exist due to mutations in the genome (82,170). 
These mutants probably occur because of immunoselective pressure. Escape mutations in 
the 'a'-determinant have been described recently in chronic hepatitis В patients who were 
treated with human monoclonal anti-S antibodies as a means of passive immunization after 
orthotopic liver transplantation (90) and after vaccination with recombinant major HBsAg 
(22). Mutations in the preS and preC/C regions, however, are seen more frequently. 
Several reports provide evidence for the involvement of these HBV-mutants in outbreaks 
of fulminant hepatitis (section 1.5.1 and 83,132,147). 
Figure 1.7 shows the mondial distribution of HBV infection. In south-east Asia and 
central Africa more than 15% of the population is found to be carrier. In Western 
countries this percentage is less than 1% although large differences exist between high-
risk groups such as intravenous drug abusers, health care personnel, haemophiliacs, 
homosexuals etc. The incidence of infection in northern Europe is also remarkably 
different from the southern European countries (Italy, Greece, Spain) where hepatitis В is 
more prevalent. 
16 
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The routes of transmission of the hepatitis В virus are essentially the same as those found 
for the AIDS virus. In the endemic areas the major transmission route is from an infected 
mother to her child at the time of birth (vertical transmission). An infected infant from an 
HBeAg positive mother has a 90% chance of developing a chronic carrier state. In high-
risk groups, Ш infection is often accompanied by hepatitis В virus infection (177). 
Figure 1.7 Mondial distribution of hepatitis B. From Szmuness et al. (ref 156). 
In the USA between 200,000 and 300,000 acute infections are still found annually despite 
vaccination programs. Before recombinant vaccines became available in 1989, vac­
cinations were performed with HBsAg, isolated from serum of chronic carriers. The 
potential hazard (not proven) of serum-derived vaccines is the presence of residual 
17 
viruses, as well as other contaminants (HIV!), despite careful inactivation. The cloning 
and high yield expression of the small HBsAg gene in yeast (20,97) was a major step 
forward. Several recombinant vaccines are available at present, yielding very good 
protective efficacies (>95%). One important problem that has to be considered is the 
evolving of vaccine-induced immune escape mutants as have been described on several 
occasions (48). However, it is still not clear whether these S-mutants are capable of 
infecting those persons that already have immunity against wild-type virus. These 
problems can eventually be overcome by including mutant S-proteins in future vaccines. 
1.5 SOME CLINICAL ASPECTS OF HEPATITIS В VIRUS 
INFECTION 
Infection with the hepatitis В virus may result in various clinical conditions, ranging from 
subclinical state with or without liver test abnormalities, acute hepatitis to chronic 
hepatitis with the development of liver cirrhosis and/or hepatocellular carcinoma 
(37,73,7η. 
In a classical case of acute hepatitis, after an incubation period of about two months 
(varying between six weeks and six months), HBeAg, HBsAg and antibodies against 
HBcAg appear in the serum, accompanied by a rise in the level of the liver enzyme 
alanine transferase (ALT) in the serum, indicating hepatocellular necrosis. In this period 
the patient may develop jaundice with or without fever. The presence of HBsAg and 
HBeAg in the serum is generally indicative of viral replication and high infectivity. 
In most cases, serum HBeAg and subsequently HBsAg disappear within three months 
while antibodies against HBeAg may be detected. After 2 to 16 weeks after the disap­
pearance of HBsAg (the window phase), antibodies against HBsAg are detectable, 
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indicating recovery and protective immunity. Less than 1 % of cases with acute hepatitis В 
may develop a fulminant hepatitis, usually associated with progressive liver failure with a 
high mortality rate (80%). 
Approximately 5 to 10% of the patients with acute hepatitis В develop chronic hepatitis. 
Chronic hepatitis В is defined by the presence of hepatitis and detectable serum HBsAg at 
least 6 months after the acute episode. It is still not known, however, what the exact 
mechanisms are affecting the development of chronic hepatitis. An impairment of 
immunity is thought to play a crucial role (79). 
1.6 HBV VARIANTS AND CHRONIC TYPE В HEPATITIS 
A number of recent reports have described the involvement of mutated hepatitis В viruses 
in chronic hepatitis B. These mutations mostly involve the preC/C region and the preS 
region (21,22,42,115,132,161,170,172). Wakita et al. showed the presence of preC 
mutated HBV variants in more than half of a group of chronic carriers (172). 
Mutated hepatitis В viruses have been reported as the causative agents for several 
outbreaks of fulminant hepatitis В in chronic hepatitis В patients (75,83,147). All these 
patients shared antibodies to HBeAg but had no detectable HBeAg, despite a positive 
serum HBV-DNA, an important marker of active viral replication. Analysis of viral 
genomes, isolated from these patients, revealed that the viruses contained a single G to A 
point mutation in the preC region at position 1896, resulting in a stop codon 
(TGG > > TAG: tryptophan > > stop). As a result, these viruses become HBeAg defi­
cient. Since these mutant viruses appear late in the course of the disease and often at or 
shortly after the onset of seroconversion from HBeAg to anti-HBeAg, it is likely that they 
evolve under immunoselective pressure. 
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HBeAg plays, together with HBcAg, a crucial role in immune mediated clearance of virus 
infected hepatocytes. Absence of HBeAg or HBcAg from the surface of the infected liver 
cell, as occurs in infections with HBeAg-deficient HBV, may lead to an impaired immune 
breakdown of these infected cells. This mechanism is considered as an important cause 
for persistence of viral replication and thus evolution to chronic hepatitis B. However, it 
is still not known what the exact mechanisms are, influencing the clinical outcome of such 
an infection: infection with HBeAg deficient hepatitis В virus sometimes leads to a 
relatively mild chronic carrier state and in other cases it leads to a fulminant hepatitis. 
Host immune responses will generally represent a critical factor in the degree of liver 
disease (section 1.7), but it is also possible that yet undefined other mutations in the viral 
genome determine the course of the disease. Some other factors might also be associated 
with severity of liver disease in infection with HBV variants: 
- Experiments with mice, transgenic for HBeAg revealed that this antigen induces im­
munological tolerance (104). Absence of HBeAg might therefore result in im­
munological intolerance and massive liver cell necrosis. 
- Chisari et al. have reported that in transgenic mice large amounts of large HBsAg 
have a cytopathic effect, mediated via interferon-gamma and tumor necrosis factor-α 
(27,28,53). These factors might also occur in mutant HBV infected cells that permit 
excessive viral replication. 
As already mentioned, mutations may also be encountered in the preS region. Several 
papers reported on the presence of preS2 deletion mutants (51,107,143). The deletions 
mostly occurred in the amino-terminal region of preS2, the region that contains both В 
and T-cell epitopes (section 1.7). Analogous to the preC mutants, these preS mutants may 
evolve because of immunoselective pressure. 
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1.7 DEVELOPMENT OF HEPATITIS В RELATED 
HEPATOCELLULAR CARCINOMA 
The hepatitis В virus is the only DNA virus, known to be directly involved in car­
cinogenesis (74,84,128,137). Epidemiological data provided evidence for the causative 
relationship between HBV infection and the development of hepatocellular carcinoma 
(HCC) (7,150). In woodchucks, chronically infected with woodchuck hepatitis virus, 
hepatocellular carcinoma will develop in all animals after two to three years of infection 
(129). 
Patients who are suffering from chronic hepatitis В for over 10 years are at risk of 
developing liver cirrhosis and/or HCC (10-15% of chronic carriers). The molecular 
mechanism of malignant transformation of liver cells in hepatitis В patients is not yet 
fully understood, although several hypotheses exist: chronic liver cell injury and liver 
regeneration increases cell turnover, which may associate with an increased susceptibility 
for gene alterations. These alterations might involve activation of oncogenes or inac-
tivation of tumor suppressor genes. These two processes are thought to be important first 
steps in carcinogenesis. 
A second process in chronic hepatitis В that may be responsible for alterations in the host 
cell genome, eventually leading to malignant transformation, is integration of viral DNA 
in the host cell chromosomes. In this regard, integrated HBV-DNA sequences can be 
demonstrated in the tumorous tissue of most patients with HCC (33,34). These in­
tegrations may lead to instability of the genome and cause microdeletions, chromosomal 
deletions and/or rearrangements (98,116). During liver cell regeneration in chronic 
hepatitis B, there will be a selection in favour of cells that grow faster because of these 
genomic alterations. Clonal expansion of these altered cells might lead to tumorogenesis. 
Integration of HBV DNA might also disregulate the cell cycle in a direct way: one 
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integration of viral DNA in a gene, closely associated with cell division, has been 
described in HCC (173). 
Although the direct repeats (DR1 and DR2) of HBV DNA certainly play a role in the 
integration process (33), integrations in the host genome are found at random. No charac­
teristic chromosomal flanking sequences are found (60,138,185). 
Recent evidence also suggests a possible role for the hepatitis Β χ antigen (HBxAg) and a 
preS/S peptide in malignant transformation (72,98). The transactivating potentials of 
HBxAg and preS/S peptide have been demonstrated in various systems (98,134,146,166). 
HBxAg up-regulates activities of several HBV promoters (the X, С and S promoter), 
НГ -І and НГ -ІІ long terminal repeat regulatory sequences and cellular promoters (B-
interferon and the proto-oncogene c-myc, 4), while the preS/S sequence has a profound 
effect on the activities of oncogenes c-fos and c-myc and the interleukin-6 gene (98). This 
has lead to the idea that the preS/S- and the X-antigen might be responsible for malignant 
transformation of hepatocytes. Several suggestions were made in the literature about the 
mechanism of trans-activation of HBxAg: 
- HBxAg itself does not bind to DNA but it might bind to transcriptional factors, 
altering their DNA- or protein binding specificities (89). 
- HBxAg contains an amino acid sequence that bears homology to serine/threonine 
kinases (175). The activity of certain transcriptional factors might therefore be 
changed, leading to disregulation of transcription. 
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1.8 SUGGESTED MECHANISMS FOR LIVER CELL INJURY IN 
HEPATITIS В 
Hepatitis В virus particles and viral antigens themselves are not considered to be cytopa-
thic. Cell lines can be transfected in vitro with the complete HBV-genome, leading to 
continuous production of infectious viral particles while ultrastructural features of these 
cells remain intact (1,2,139). Tissues from transgenic mice that produce and secrete viral 
antigens or particles also show no sign of cytopathicity (44,45,53). However, livers of 
mice, transgenic for the large HBsAg gene, show a profound accumulation of non-
secretable HBsAg in the endoplasmic reticulum (ER), giving rise to 'ground-glass' cells 
(27,28,53). These high concentrations of HBsAg appear to render the cell sensitive to 
interferon-gamma (IFN-Γ) and tumor necrosis factor-alpha (TNF-α) induced necrosis. 
There are two models that may account for the mechanism of liver cell necrosis. The 
generally accepted model (figure 1.8) is that in acute hepatitis, viral antigens (especially 
HBeAg and/or HBcAg and preS proteins) are displayed on the hepatocyte surface 
(100,106,118). Cells, exposing these antigens are recognized and attacked by sensitized 
cytotoxic T-cells, involving the expression of major histocompatibility complex (MHC) 
class I antigens on the hepatocyte membrane (9,30,36,100,106,118,120,123). Following 
binding, the infected cell is lysed by the T-cell. Following hepatocellular necrosis viral 
particles are released and can be neutralized and cleared by circulating antibodies. 
The role of the immune system in hepatocellular necrosis in hepatitis В is supported by 
the fact that immunosuppressive and cytotoxic therapy co-incides with reactivation of 
hepatitis (86): during therapy, the virus replicates without constraint with massive 
expression of viral antigens in hepatocytes. Cessation of therapy results in recovery of 
immunity and subsequent massive attack of cytotoxic T-cells resulting in fulminant 
hepatocellular necrosis with possible fatal outcome. The severe hepatitis in patients with 
infection of HBeAg deficient HBV variants may also be due to a similar mechanism 
(1.3.3.1 and 1.5). 
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Figure 1.8 Schematic representation of immune mediated clearance of infected cells and virus. 
From van Ditzhuijsen, thesis 1988. 
Very recently the group of Gules et al. postulated an alternative model for liver cell 
injury (S3). This hypothesis implies that intracellular HBsAg alters the hepatocyte 
physiology in such a way that the cell becomes vulnerable to the cytotoxic effects of 
physiological concentrations of interferon-gamma. It remains however to be determined 
whether the intracellular concentrations of HBsAg in infected cells are sufficiently high to 
induce this effect. 
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1.9 TREATMENT OF HEPATITIS В 
As discussed in the previous section, hepatic injury is thought to be mediated by the 
immune system. Therefore two regimes for treatment of chronic hepatitis В can be 
employed: antiviral and immunomodulatory agents. Antiviral agents such as acyclovir and 
vidarabine (157) have been shown to be unsucccsful. The same applies to immune 
modifiers as interleukin-2 and levamisole (91,93). 2',3'-dideoxynucleoside analogues, 
acting as chain terminators in DNA synthesis, have been shown to inhibit reverse 
transcriptase activity of human immunodeficiency virus (HIV) in vivo (47,186) and might 
be effective on the hepatitis В viral reverse transcriptase. In animal models, inhibition of 
duck HBV replication has been demonstrated by these agents (71). However, no benefi­
cial effect in humans was found so far. 
The only treatment so far that has been clearly shown to be effective in a significant 
number of cases, is interferon-α (IFN-a) therapy. In vitro, interferons have been shown 
to inhibit HBV replication (58,65). 30%-50% of IFN-a treated patients with chronic 
hepatitis В show HBeAg seroconversion with concomitant loss of serum HBV-DNA 
(85,120,122). However, IFN-a may induce severe side effects, even with a lethal 
outcome. Treatment with IFN-a might also lead to the emergence of mutant viruses that 
can escape the immune attack (56). 
An alternative approach to treatment of chronic hepatitis B, which might become impor­
tant in the future, is the use of anti-sense oligonucleotides. When these synthetic DNA's 
are brought into the cell, they bind specifically to complementary RNA, thus preventing 
correct translation. Anti-sense oligonucleotides, directed against HBsAg RNA have been 
shown to inhibit synthesis of HBsAg in vitro (54). 
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1.10 HOST AND TISSUE TROPISM OF HEPATITIS В VIRUS 
Leenden WPJ, Hertogs K, Moshage H, Yap SH. 
Liver 1992:12; 51-55 
(shortened version) 
The tremendous developments in molecular and cellular biology in recent years have 
unravelled the fundamental but complex interactions between virus and host cell and 
between virus and its host organism during infection. 
When infecting a host organism and replicating within cells, viruses proceed through an 
orderly series of steps. These steps include entry into the host organism, primary repli-
cation, spread to distant sites and secondary replication (167). A successful viral infection 
can only be achieved if the infected cells provide an "appropriate environment" for viral 
survival and efficient development and propagation. 
Viral infection and replication are functions of the viral delivery system and viral 
contents. The elementary structure of a virus is designed to fulfill these two fundamental 
functions. The delivery system consists of components forming external structures of viral 
particles (surface components), and the payload carried inside a viral particle and con-
taining the genome and associated components which protect the genome from degrada-
tion, supplies functions for initiating steps of replication. These components may aid in 
translating or transcribing the genome, integrating it into the host DNA (if necessary) or 
keeping it quiescent (114). 
Components of the viral delivery system initiate the replication cycle by attaching to 
"receptors" on the cell surface and initiating penetration into the cytoplasm. Cytoplasmic 
penetration is usually associated with a loss of external components (uncoating). Viruses 
that replicate within the nucleus have additional delivery functions that permit viral 
components to be introduced into the nucleus. Studies on basic aspects of viral infection 
as outlined above, are obligatory for a better understanding of the mechanisms by which 
viruses cause disease. 
Although much information on the molecular biology of HBV has been obtained by analy-
zing animal models and by expression of one or more genes in transfected mammalian 
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cells (3,94,102,130), the mechanisms that may affect the host and tissue tropism of the 
virus are not yet well understood. Evidence for the hepatocyte restriction of HBV repli­
cation comes mainly from clinical data and studies on HBV DNA transcription (23,49). 
Two basic mechanisms are considered and expected to be important in determining the 
tissue- and host -restricted replication of HBV: 
1) a molecular recognition by defined viral envelope domains of species- and cell-spe­
cific constituents expressed on the cell surface of the host (receptor theory) and 
2) involvement of hepatocyte-specific cytoplasmic and/or nuclear factors required for 
efficient propagation of HBV (theory of appropriate intracellular environment for viral 
survival and development). 
1) Hepatitis В virus receptors 
The receptor is often a key, and in some cases the sole determinant of viral tropism. Such 
a receptor for HBV has not yet been identified. However, binding domains located on the 
virion surface and possibly mediating host- and tissue-specific recognition have been 
studied intensively in the last decade (52). Since amino acid sequences encoded by the 
preS region are located exteriorly on the hepadna virus envelope, it has been suggested 
that domains mediating host- and tissue-specific recognition are located within this 
sequence. 
In 1979, Imai et al. (64) reported a receptor for polymerized human and chimpanzee 
albumin on hepatitis В viral particles co-occurring with HBeAg. Subsequent studies 
(66,88) showed that the preS2 region contains the binding domain of artificially 
polymerized human serum albumins (pHSA) and that liver cells bind to pHSA, although 
this binding is not species specific (163). Plasma membranes from human liver are also 
shown to bind to natural HBs spheres (127) or recombinant middle HBs protein (125) 
when they are pretreated with pHSA. Furthermore, Neurath et al. (110) demonstrated that 
an anti-serum against a preS2 peptide (residues 1-24) was able to neutralize a defined 
HBV inoculum by showing that it was no longer infectious in experimentally challenged 
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chimpanzees. In addition, immunization of chimpanzees with a conjugate of a preS2 
peptide (aminoacid residues 14-32) with keyhole limpet hemocyanin protected them 
against HBV challenge (67). All the findings, mentioned above, suggested that the preS2 
domain would act via pHSA as a species· and organ specific attachment site of HBV. The 
binding site for pHSA is located within the amino acid sequence 17-28 of the preS2 
domain (76). In recent years, however, the importance of the pHSA binding was placed 
in doubt by the observation that pHSA was only able to bind if it was cross-linked by 
glutaraldehyde (180) or transglutaminase (1S9). In addition, some observations suggested 
that the preSl domain, and not the preS2 domain is probably the most important attach-
ment site to liver cells. Thus Neurath et al. (I l l) found that suspended HepG2 cells 
bound to immobilized HBV particles and that peptide (aminoacid residues 21-47) of preSl 
and antibodies against this peptide competed with or inhibited this binding. 
This finding was confirmed by Pontisso et al. (125) using recombinant large HBsAg and 
immobilized plasma membranes from human liver. A monoclonal antibody directed 
against an epitope of preSl (amino acid 30-36), but not a monoclonal antibody specific 
for another epitope of preSl (amino acid 94-117) or monoclonal antibodies against preS2 
inhibited this binding. According to Neurath & Strick, the sequence around the binding 
site is highly homologous to a sequence of IgA (112) and apparently binds to an IgA 
receptor of the liver (126). The preSl attachment site recognizes a receptor not only on 
liver cells, but also on monocytes and lymphocytes (124). Furthermore, natural HBV 
inocula have been neutralized by rabbit antisera against preSl (amino acid 21-47) (113), 
and chimpanzees have been directly immunized by preSl (amino acid 12-47) (158). 
In view of the findings, mentioned above, and despite the fact that vaccination with major 
HBsAg protects so well against HBV infection, major HBsAg was not considered as an 
important attachment protein of HBV. However, using recombinant large and major 
HBsAg in binding studies, we have recently found that major HBsAg was able to bind 
specifically to human hepatocytes, human fibroblasts and human blood mononuclear cells. 
This binding could be inhibited by recombinant middle protein but not by recombinant 
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large protein. No binding could be demonstrated between large HBsAg and human 
hepatocytes (80). Nevertheless, large protein bound specifically to plasma membranes 
derived from human liver tissue, human fibroblasts and HepG2A16 cells. This binding 
could be partially inhibited by the major protein and by a synthetic preSl peptide (80). 
These results support the assumption that HBV attachment and penetration into human 
hepatocytes is mediated by specific receptors recognizing an amino acid sequence in the 
S-region. This recognition site is not displayed by the recombinant large protein. 
However, the large protein is recognized in its preSl region by a receptor molecule 
located on the inner surface of the plasma membrane or intracellular membranes of 
human hepatocytes and of some other cell types derived from human tissue. This finding 
is supported by experiments conducted by Michalak et al. (101), which were undertaken 
to identify the existence of a hepatocyte binding domain within the external amino-
terminal sequence of the WHV (woodchuck hepatitis virus) preSl-encoded protein. The 
probing of liver, spleen, pancreas and kidney homogenates derived from normal wood-
chucks, a human and mice with the radiolabeled peptide showed its exclusive binding to 
woodchuck hepatic and splenic tissues. The peptide-binding component was found to be 
particularly enriched in the mitochondrial fraction and was not detected in plasma mem-
branes. 
In summary, the results of studies on binding domains located on the virion surface 
possibly mediating host- and tissue-specific recognition are still controversial. Further and 
detailed studies on the nature of specific cellular receptors and the corresponding virus 
binding sites remain to be done. 
2) Hepatocyte specific cytoplasmic and/or nuclear factors required for efficient 
propagation of HBV 
Following surface binding, virions are taken up into the hepatocyte. The mechanism of 
this uptake process for HBV is still unknown. Once inside the cell, the whole cascade of 
reactions as described in section 1.3.S might start, provided that the appropiate conditions 
are present. 
In general, the regulation of genes that encode messenger RNA in higher eukaryotes 
requires two DNA regulatory sequence elements: promoters and enhancers. Promoters are 
located immediately upstream from the start site of transcription and are typically about 
100 base pairs in length (92). The promoters are required for accurate and efficient 
initiation of transcription, whereas enhancers increase the rate of transcription by 
increasing promoter activity. The distinctive characteristic of enhancers is that they can 
act as CIS-linked promoters at great distance in an orientation- independent manner, even 
downstream from the transcription unit. Viral promoters and enhancers are active in most 
cell types, and the level of their activity can be regulated by both viral and cellular gene 
products (92). The HBV genome is found to have four promoters: preSl promoter (SPI) 
for the 2.4 Kb RNA, S promoter (SP2) for the 2.1 Kb RNA; core promoter (CP) for the 
3.5 Kb RNA (26) and X promoter (XP) for the 0.7 Kb RNA (69). Additional CIS-acting 
viral elements, enhancers (E), act on both homologous and heterologous promoters 
(17,174,178,182). The S gene transcript of 2.1 Kb can be synthesized in a wide variety of 
transfected cell lines derived from diverse tissues and species (38,78,153). However, the 
pregenome transcript of 3.5 Kb can be synthesized only in well-differentiated hepatoma 
cell lines and not in most nonhepatic cell lines transfected with viral DNA (19,155,164, 
176). The preSl promoter SPI is also preferentially active in a differentiated hepatoma 
cell line (133), indicating its tissue-specific character. Nuclear factors of well-differen-
tiated human hepatoma cell lines have been thought to be responsible for this hepatocyte-
specific transcription by the specific binding of these factors to HBV enhancer and/or 
promoter elements leading to hepatocyte-specific replication of HBV (8,70,119,175). Such 
cellular gene products necessary for efficient propagation of intact and infectious viral 
particles have not been identified yet. However, the application of recombinant DNA 
techniques to the study of eukaryotic gene regulation, the advances in the characterization 
of the protein factors that specifically interact with DNA sequences to promote or repress 
transcription, and the recent development of cell-specific in vitro transcription systems 
will undoubtedly lead to a greater understanding of the mechanism of efficient 
propagation of HBV and the related mechanism of host and tissue tropism of HBV. More 
information concerning the mechanism by which viral infection in the liver can be 
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modulated or eliminated through selective processes could allow the development of novel 
strategies to eliminate HBV from infected patients. In addition, identification of the HBV 
receptor could allow the development of soluble receptor molecules or analogues that can 
block viral attachment and absorption and could be useful in post-exposure prophylaxis, 
as an adjunct to passive and active immunization and for treatment of chronic carriers. 
33 
1.11 BACKGROUND AND AIM OF THE PRESENT STUDY 
Although the strict host and tissue tropism of the hepatitis В virus cannot be explained 
solely by the existence of a specific receptor (section 1.10), the binding of the virus to the 
hepatocyte is an essential step for infection. Knowledge of such a receptor would facilitate 
future research concerning HBV infection and might eventually have important 
implications for prevention of infection and for treatment of chronic hepatitis В patients. 
The goal of this investigation was to identify and to characterize the receptor protein(s), 
present on human liver cells, responsible for virus binding and subsequent penetration and 
replication. 
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ABSTRACT 
A likely mechanism of the strong hepatotrophism of the hepatitis В virus is the 
presence of specific receptors for the surface antigen of hepatitis В virus on 
hepatocyte membranes. To examine this hypothesis, we have performed binding 
studies using recombinant large (preSl + preS2 + S) and major (S) proteins with 
adult human hepatocytes, rat hepatocytes, human fibroblasts, human peripheral 
blood mononuclear cells and plasma membranes derived from these cell types. We 
found that major HBsAg was able to bind specifically to human hepatocytes, human 
Fibroblasts and human blood mononuclear cells. This binding could be inhibited by 
recombinant middle (preS2+S) protein but not by the recombinant large protein. No 
binding could be demonstrated between large HBsAg and human hepatocytes. 
However, large protein bound specifically to plasma membranes derived from human 
liver tissue, human fibroblasts and HepG2A16 cells. This binding could be partially 
inhibited by the major protein and by a synthetic preSl peptide but not by a 
synthetic preS2 peptide. These results support the assumption that hepatitis В virus 
absorption and penetration into human hepatocytes is mediated by specific receptors 
recognizing an amino acid sequence in the S-region. This recognition site is not 
displayed by the recombinant large protein. However, the large protein is recognized 
by its preSl region and by a second binding site in the S-region by a receptor 
molecule, located in the inner surface of the plasma membranes or intracellular 
membranes of human hepatocytes and of some other cell types derived from human 
tissue. (Hepatology 1990;12:141-147.) 
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INTRODUCTION 
HBV infection is a major health problem. It has been estimated that more than 200 
million people worldwide are infected with the virus, with a mortality rate of about 2 
million annually (1). 
The HBV specifically causes liver disease and is a member of the hepadnaviruses, which 
include the woodchuck hepatitis virus, the ground squirrel hepatitis virus, the duck 
hepatitis virus and the recently discovered tree squirrel hepatitis virus (2). These viruses 
cause liver disease only in susceptible hosts. The mechanism(s) underlying the strong 
tissue tropism and the host specificity of these viruses are as yet not fully under-stood. 
The infectious virion or Dane particle (3) of HBV is a core coated by an envelope of 
HBsAg. HBsAg is a product of the HBsAg gene of HBV DNA. The open reading frame 
of this HBsAg gene contains three adenine, thymidine and guanosine (ATG) initiation 
codons for protein synthesis. The most downstream situated initiation site generates the 
major HBsAg containing 226 amino acids. The second ATG site, 165 bases upstream, ini-
tiates the production of the major protein extended with a sequence of 55 amino acids 
known as preS2, thus yielding middle protein. The third ATG codon on the S-gene, 3S7 
bases further upstream, codes for another 119 to 128 amino acid extension known as 
preSl, thus coding for the large protein (4). 
To determine whether surface proteins of HBV might be involved in the specific viral 
penetration and infection of hepatocytes of susceptible hosts, we have examined the 
binding of recombinant large and major HBsAg to intact adult human hepatocytes. The 
results were compared with those obtained from experiments using intact rat hepatocytes, 
human fibroblasts and human blood mononuclear cells and with plasma membranes 
prepared from human liver tissue, rat liver tissue, human fibroblasts, human blood 
mononuclear cells and HepG2A16 cells. 
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MATERIALS AND METHODS 
Isolation of Plasma Membranes. 
For the isolation of plasma membranes, human liver tissue (stored at -80°C) obtained 
from six different postmortem organ donors was pooled. (Permission for use of the livers 
was obtained from the family and the investigation was approved by the medical ethical 
committee for human experimentations.) Plasma membranes were isolated according to 
Hubbard, Wall and Ma (5) as described by Pontisso et al. (6). In short, 50 gm of liver 
tissue was homogenized in 0.25 STM (0.25 mol/L sucrose, 5 mmol/L Tris-HCl [pH 7.2], 
1 mmol/L MgClJ with a Dounce homogenizer. The homogenate was filtered through a 
100-μπι mesh nylon filter, and the filtrate was centrifugea at 300 g at 4°C in 0.25 STM 
for 10 min. The pellet was washed in the same buffer, and the supematants were pooled 
and centrifuged at 1,500 g (4°C) for 10 min. The pelleted membranes were resuspended 
in 100 ml 0.25 STM and 2 mol/L STM (2 mol/L sucrose, 5 mmol/L Tris-HCl [pH 7.2], 
1 mmol/L MgClj) was added until a density of 1.18 gm/ml was reached. Four milliliters 
of 0.25 mol/L STM was layered over 33 ml of this suspension and centrifuged for 1 hr at 
4°C at 82,000 g. The membranes that floated on the 1.18 gm/ml sucrose buffer were col­
lected. Finally, they were brought to a density of 1.05 gm/ml with 0.25 STM and pelleted 
at 20,000 g for 15 min. The membranes were frozen in liquid nitrogen and stored at 
-80°C until use. 
Rat liver (Wistar rats) plasma membranes and plasma membranes from human fibroblasts, 
human blood mononuclear cells and HepG2A16 cells were prepared according to the 
same method. 
Radiolabeling of Proteins. 
Recombinant large, middle and major HBsAg (yeast derived) were a kind gift of Dr. 
William J. Miller (Analytical Research and Development, MSD laboratories, West Point, 
PA). Five micrograms of large or major HBsAg were labeled with 0.5 mCi 125I (Amer-
sham, Buckinghamshire, England) by incubation for 15 min at room temperature with 
Iodogen (l,3,4,6-tetra-chloro-3a,6or-diphenyl-glycouriI; Pierce, Rockford, II) according to 
the method of Salacinski (7). Free iodine was removed by passage over a Sephadex G75 
column (Pharmacia, Uppsala, Sweden). Proteins were stored at 4°C until use. The 
specific activity varied from 10 to 15 million cpm/pg for large and major HBsAg. 
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Binding of Radiolabeled Ligand to Plasma Membranes. 
Two different methods were used for binding studies on plasma membranes. 
In the first method, 10 /ig of liver plasma membranes (determined by the method of 
Lowry et al. [8]) was spotted on 6 mm φ 0.45 μπι nitrocellulose filters (Schleicher & 
Schuil, Dassel, West Germany). The filters were dried at room temperature for 1 hr and 
were subsequently washed several times in PBS. After blocking with 5% (wt/vol) milk 
powder in PBS for 1 hr at room temperature and washing, various amounts of radiola­
beled ligands (ranging from 0 to SO ng) were added, and the filters were incubated for 2 
hrs at room temperature in a total volume of 100 μΐ of PBS/ 1 mmol/L СаСІ2 in 96 wells 
dishes. Because no significant differences were found between the specific bindings at 4°C 
(based on the findings of an initial study), for convenience the next experiments were 
performed at room temperature. After incubation, the filters were washed four times in 
PBS and the bound radioactivity was determined. For the determination of the nonspecific 
binding, incubation was also performed in the presence of 20-fold excess of unlabeled 
ligand. 
In method 2, SO μg of plasma membranes was suspended in 500 μΐ of Williams medium 
E (Flow Laboratories, Irvine, Scotland), containing 2 mmol/L L-glutamine, 100 ^g/ml 
vancomycin, 2.S ^g/ml amphotericin В, SO Mg/ml gentamycin, 20mU/ml insulin and SO 
μιηοΙ/L dexamethasone (binding medium) and 2% BS A and was incubated in a 
polypropylene cap for 1 1/2 hr at 4°C to minimize nonspecific binding. After this 
blocking medium was removed, the plasma membranes were incubated for 2 hr at room 
temperature with 125I labeled ligands in binding medium. Plasma membranes were washed 
two times in binding medium by centrifugation at 4°C for 1 min at 10,000 g, and bound 
radioactivity was determined. Nonspecific binding was determined by incubating plasma 
membranes with radiolabeled ligand in the presence of 20-fold excess of unlabeled ligand. 
Isolation and Cryopreservation of Hepatocytes. 
Human hepatocytes were isolated from liver tissue obtained from postmortem kidney 
donors by two-step collagenase perfusion according to the method as described by Rijntjes 
et al. (9). Collagenase, purified from Clostridium histolyticum, was purchased from 
Boehringer Mannheim (Mannheim, W. Germany). Hepatocytes were suspended in ice-
cold Williams medium E containing 10% DMSO and 20% FCS in a density of 5 to 
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15x10* viable cells/milliliter and cryopreserved as described previously (9). Freezing was 
performed in storage vials (NUNC Inc., Naperville, IL) using a Cryosan BV-4 program-
mable freezer (Cryosan Inc., Wobum, MA). Cooling was obtained by computer-control-
led liquid nitrogen evaporation. After maintaining the temperature at 0°C for 5 min, tem-
perature reduction was initiated at a rate of 1.5°C/min for 20 min followed by a freezing 
rate of 7°C/min for 10 min. The cells were then stored at -150°C (vapour phase of liquid 
nitrogen). Rat hepatocytes (Wistar rats, 200 gm) were isolated and cryopreserved accor-
ding to the same method. 
Thawing of Cryopreserved Cells. 
Cryopreserved hepatocytes, fibroblasts and HepG2A16 cells were thawed by immersion 
of the storage vial in a 37°C water bath. Cells were diluted immediately after thawing 
with ice-cold culture medium and were washed twice by centrifugation (50 g, 4°C) to re-
move the cryoprotectants. Fibroblasts, isolated from human foreskin, were grown in 
Dulbecco's modified essential medium (DMEM, Flow Laboratories) supplemented with 5 
mmol/L 1-glutamine, 200 IU penicillin/ml and 200 IU streptomycin/ml. HepG2A16 cells, 
kindly provided by Dr. Knowles (Wistar Institute of Anatomy and Biology, Philadelphia, 
PA), were maintained in the same medium. After harvesting the cells by trypsinization, 
the cells were cryopreserved and stored until use. 
Binding of Radiolabeled Ligand to Intact Cells. 
Approximately 100,000 cells (human or rat hepatocytes, human fibroblasts or blood 
mononuclear cells obtained from the buffy coat of healthy blood donors by centrifugation 
on a Ficoll cushion for 20 min at 2,000 rpm in a Christ centrifuge) were suspended in 1 
ml binding medium. Radiolabeled protein was added in various amounts, ranging from 0 
to 50 ng, in the absence or presence of excess unlabeled ligand to determine nonspecific 
binding. The cells were incubated on a rocking platform (100 rpm) for 2 hrs at 4°C. 
Subsequently, the cells were washed four times in PBS by centrifu-gation (100 g, 4eC). 
After the bound radioactivity was determined, the cells were treated with 0.5 N NaOH 
for protein determination, according to the method of Lowry et al. (8). Results were 
expressed in counts per minute per microgram cellular protein. All experiments were 
carried out in triplicate. 
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RESULTS 
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Figure 2.1 (a) Binding of recombinant mI-major HBsAg to isolated human hepatocytes in 
suspension. Approximately Iff cryopreserved human hepatocytes were incubated for 2 hr at 4°C 
with various amounts of '"¡-major HBsAg. Total binding was measured after washing the cells 
four times in binding medium by centrifugation at 100 g, 4Ό. Nonspecific binding was determined 
by adding a 20-fold excess unlabeled major HBsAg in the incubation. The specific binding was 
obtained after subtracting the nonspecific binding from the total binding. Values were corrected 
for cellular protein content and expressed as picograms per micrograms cellular protein. The 
range is indicated by error bars, (b) Scatchard analysis of the binding of recombinant '"¡-major 
HBsAg to isolated human hepatocytes in suspension. Kd-dlssociation constant. 
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Binding of Recombinant HBsAg to Human Hepatocytes. 
To study the bindings of recombinant large and major HBsAg to human hepatocytes, 
cryopreserved human hepatocytes in suspension culture were used. Cryopreserved hepa-
tocytes had been stored for 30 to 48 months before the experiments. The viability of 
hepatocytes as determined by trypan blue exclusion averaged 60% (45% to 70%). Despite 
"bleb" formation in approximately 10% to 20% of the cells, frozen cells showed little 
changes immediately after thawing when their ultrastructural features were compared 
with non-frozen hepatocytes (9). For the binding study, approximately 100,000 cells were 
incubated in 0.S ml of binding medium with varying amounts of radiolabeled HBsAg. As 
shown in Figure 2.1a, specific and saturable binding was obtained between major HBsAg 
and human hepatocytes. Scatchard analysis showed that the resulting data were best fit by 
one line characterized by a dissociation constant (Kd) of 1 pmol/L with approximately 
50,000 binding sites per cell (Figure 2.1b). The binding of major HBsAg to human 
hepatocytes could be inhibited by recombinant middle protein but not by recombinant 
large protein (Figure 2.2). Furthermore, no specific binding was obtained between human 
hepatocytes and recombinant large HBsAg (Figure 2.3). 
Binding of Recombinant Major HBsAg to Rat Hepatocytes, Human Fibroblasts and 
Human Peripheral Blood Mononuclear Cells. 
The results of the bindings of major HBsAg to rat hepatocytes, human fibroblasts and 
human blood mononuclear cells are demonstrated in figure 2.4. There was no specific 
binding between major HBsAg and rat hepatocytes. However, a specific binding was ob-
tained between major HBsAg and human fibroblasts or human peripheral blood mono-
nuclear cells. 
Binding of Recombinant HBsAg to Plasma Membranes Prepared from Human 
Hepatocytes. 
From the experiments using intact cells it was apparent that there was no specific binding 
between recombinant large HBsAg and human hepatocytes despite the fact that a specific 
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Figure 2.2 Influence of recombinant middle and 
large HBsAg on the binding of recombinant J 27-
major HBsAg to isolated human hepatocytes. 
Experimental conditions were as described in 
Figure 2.1, except that a 20-fold molar excess 
middle or large HBsAg was added in the in­
cubation. Amount of radiolabeled protein was 20 
ng, the minimum amount at which saturation oc­
curred (Figure 2.1a). The results were expressed 
as percentage of bound "Ί-major HBsAg in the 
absence of unlabeled protein in the incubation. 
As a control, a 20-fold excess major HBsAg was 
added. 
Figure 2.3 Binding of "Ί-large HBsAg to isolated 
human hepatocytes. Experimental procedures were 
as described in Figure 2.1. For each point, 20 ng of 
radiolabeled large HBsAg, the amount at which 
major HBsAg saturates hepatocytes, was added with 
increasing amounts of unlabeled large HBsAg (x-
axis). The results were expressed as percentage of 
total binding of 'BI-large HBsAg to human 
hepatocytes in the absence of unlabeled protein. The 
initial concentration of the unlabeled Large HBsAg 
(x-axis) was 250 ßg/ml. One hundred percent was 
approximately 80 cpmfyg cellular protein in this ex-
periment. 
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Figure 2.4 Binding of '"I-major HBsAg to 
various cell types. Human hepatocytes (HH), 
rat hepatocytes (RH), human peripheral blood 
mononuclear cells (HBMC) and human fibro­
blasts (HF) were incubated with 20 ng of'aI-
major HBsAg in the absence or presence of a 
20-fold excess unlabeled protein fmdicated as 
'total binding' and 'excess major HBsAg' 
respectively). The results were expressed as 
percentage of total binding of '"I-major 
HBsAg in the absence of unlabeled major 
HBsAg. (100% represents per microgram 
cellular protein: HH=100 cpm; RH=1S0 
cpm; HBMC=450 cpm; HF=90 cpm in this 
experiment). 
binding of recombinant major HBsAg was 
obtained. Since these findings were in 
conflict with those reported in the 
literature (6,10), we performed similar 
binding experiments as described in those 
reports using liver tissue derived plasma 
membranes immobilized on nitrocellulose 
filters. As shown in Figure 2.5a, recom­
binant large HBsAg specifically bound to 
plasma membranes prepared from human liver tissue. The Scatchard analysis showed two 
lines, one describing a binding with a Kd of 0.9 pmol/L and another with a Kd of 3.4 
pmol/L (Figure 2.5b). To determine which regions of the large HBsAg (preSl, preS2 or 
major HBsAg) were responsible for the attachment of the recombinant large HBsAg to 
human liver plasma membranes, the binding of 125I-large HBsAg to human liver plasma 
membranes was studied in the presence of excess (20 χ molar ratio) unlabeled preSl (aa 1 
to 119), preS2 (aa 1 to 55) or recombinant major HBsAg. As shown in Figure 2.6, the 
preS2 peptide was not able to block the binding of recombinant large HBsAg to human 
liver plasma membranes. However, the preSl peptide and recombinant major HBsAg 
inhibited the binding of recombinant large HBsAg by 20% and 60% respectively, despite 
these findings, we were not able to show specific binding between recombinant 1MI-major 
HBsAg and human liver plasma membranes (data not shown). 
HBMC 
total binding 
excess major HBsAg 
56 
CHAPTER 2: BINDING OF THE MAJOR HBsAg TO HUMAN HEPATOCYTES 
1251-large HBsAg bound(ng) 
2M0-
180-
1.20 
060 
0.00 
bound/free («10"J) 
\ 
50 100 
1251-large HBsAg added (ng) 
Δ total binding 
• specific binding 
* aspecific binding 
0.50 1.00 1 50 2 00 
bound (ng) 
Figure 2.5 (a) Binding of 123I-iarge HBsAg to human liver plasma membranes immobilized on 
nitrocellulose filters. Experimental procedures are as described in "Materials and Methods", (b) 
Scatchard analysis of the binding of recombinant '"¡-large HBsAg to human plasma membranes 
on filters. Kd=dissociation constant. 
To further examine whether the inability of recombinant major HBsAg to bind to human 
liver plasma membranes was due to experimental conditions, we designed an alternative 
assay in which plasma membranes were incubated in suspension with radiolabeled ligand. 
In this system, in addition to the specific binding between 125I-large HBsAg and human 
liver plasma membranes similar to those demonstrated by human liver plasma membranes 
immobilized on nitrocellulose filters, a specific binding was also found between recom-
binant major HBsAg and human liver plasma membranes. The resulting data of a Scat-
chard analysis were best fit by one line showing a Kd of 0.7 pmol/L. Moreover, the 
binding of recombinant major HBsAg could be blocked by recombinant large HBsAg 
(data not shown). 
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Figure 2.6 Influence of recombinant major 
HBsAg, preS2 (1 to 55) and preSl (1 to 119) 
on the binding of ,2SI-large HBsAg to human 
liver plasma membranes immobilized on filters 
or in suspension. Experiments were carried 
out in the absence or presence of a 20-fold 
molar excess of major HBsAg, preS2 orpreSl 
peptides. Twenty nanograms of radiolabeled 
large HBsAg were used in the incubation. The 
results were expressed as percentage of 
specifically bound "Ί-large HBsAg in the 
absence of unlabeled proteins in the in­
cubation. One hundred percent represents 
7,000 cpm. No differences of the bindings 
were found between experiments when plasma 
membranes immobilized on filters or in 
suspension were used. 
Binding of Recombinant Large HBsAg to Plasma Membranes Prepared from Rat Liver 
Tissue, Human Fibroblasts, Human Peripheral Blood Mononuclear Cells and HepG2A16 
Cells. 
The results of the binding of recombinant large HBsAg to plasma membranes prepared 
from human and rat liver tissue, human fibroblasts, human peripheral blood mononuclear 
cells and HepG2A16 cells are shown in Figure 2.7. Recombinant large HBsAg was able 
to bind specifically to plasma membranes prepared from human liver tissue, human 
fibroblasts and HepG2A16 cells. No specific binding was obtained between recombinant 
large HBsAg and plasma membranes derived from rat liver tissue or human peripheral 
blood mononuclear cells. 
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Figure 2.7 Binding of recombinant '"¡-large 
4BsAg to plasma membranes derived from 
urious cell types, '"¡-large HBsAg was in-
rubated with approximately 50 μ% plasma 
nembranes derived from human and rat liver 
issue (HH and RH), human fibroblasts (HF), 
human peripheral blood mononuclear cells 
(HBMC) or HepG2A16 cells In the absence 
(total binding) or presence of a 20-fold excess 
}f unlabeled large HBsAg. Experimental 
procedures are as described in "Materials and 
Methods'. As in all inhibition experiments, 20 
ig of radiolabeled llgand was added in the 
incubation. The results were expressed as per­
centage of binding to plasma membranes of 
each cell type in the absence of unlabeled 
aroteln. (HL: 100% =9,000 cpm; RL: 100% = 
6,500 cpm; HF: 100% =5,700 cpm; HBMC: 
100%=6,600 cpm; HepG2A16: 100% = 
5,000 cpm) 
binding of large HBsAg to PMV 
120% τ 
total binding 
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DISCUSSION 
The mechanisms of initiation of infection, of attachment to the hepatocyte plasma mem­
brane and of entry of HBV into the cell have not yet been determined. However, it is 
likely that HBV, similar to other viruses (11), uses specific receptor molecules for ab­
sorption followed by penetration into the hepatocytes. Studies on the binding of hepatitis 
В virus surface proteins to plasma membranes of human hepatocytes is an appropriate 
means of evaluating the mechanism of attachment of HBV to hepatocytes and the 
initiation of infection. Pontisso et al. (6) recently reported that only particles composed of 
large HBsAg were capable of efficiently binding directly to human liver plasma mem­
branes. Middle and major HBsAg particles, which lack the preSl amino acid sequence of 
large HBsAg, were not able to bind to these membranes. These findings, obtained by a 
solid-phase assay in which wells were coated with liver plasma membranes were con­
sistent with our results in the present study using human liver plasma membranes immo­
bilized on nitrocellulose filters. Scatchard analysis showed that the binding of large 
HBsAg was characterized by two Kd's of 0.9 and 3.4 pmol/L. Although this binding 
could be inhibited by excess preSl peptide and recombinant major HBsAg, 125I-labeled 
recombinant major HBsAg did not bind efficiently to human liver plasma membranes in 
this system. In contrast, in an alternative system using a suspension of plasma mem­
branes, we were able to demonstrate not only a specific and saturable direct binding 
between recombinant large HBsAg and human liver plasma membranes but also a specific 
and saturable binding between recombinant major HBsAg and human liver plasma 
membranes. This binding has a Kd of 0.7 pmol/L and was consistent with the results 
obtained from experiments using intact hepatocytes. The inability of plasma membranes, 
spotted on nitrocellulose filters, to bind recombinant major HBsAg is, therefore, very 
likely due to blockage of the binding sites of these membranes by the solid phase. 
Although recombinant large HBsAg can bind efficiently to human liver plasma membra-
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nes, specific binding was not obtained between recombinant large HBsAg and intact 
human hepatocytes. Since the outer surface of plasma membrane vesicles is composed of 
the outer and inner surface of plasma membranes and perhaps also of intracellular 
membranes, present as a contaminant, the above findings suggest that recombinant large 
HBsAg binds specifically to the inner surface of plasma membranes or to intracellular 
membranes by its preSl sequence and by a second binding site located in the S-region. 
Although a loss of binding sites during preparation of hepatocytes could explain the 
inability of large HBsAg to bind to isolated hepatocytes, it seems unlikely that the proce-
dure would lead to loss of large HBsAg binding sites but not of major HBsAg binding 
sites. 
The results from the experiments using recombinant major HBsAg on isolated hepatocytes 
support the assumption that virus absorption and penetration into human hepatocytes are 
mediated by specific receptors recognizing an amino acid sequence in the S-region. This 
recognition site is also displayed by the recombinant middle HBsAg but not by the 
recombinant large HBsAg. It seems likely therefore that the presence of the preSl 
sequence in large HBsAg in a certain way blocks the binding site on the S-region. 
Large protein is recognized by its preSl region and by a second binding site in the S-
region by a receptor molecule presumably on the inner surface of plasma membranes or 
intracellular membranes. The biological importance of these findings is unclear at present. 
However, it has been shown that major HBsAg is readily secreted from hepatocytes from 
transgenic mice (12) and from transfected cells (13-17), whereas large HBsAg is not. The 
property of large HBsAg of efficiently binding to the inner surface of plasma membranes 
or intracellular membranes of human hepatocytes and some other cell types derived from 
human tissue may be relevant to the role it plays in the assembly, transport and secretion 
of viral and subviral particles. 
The capability of human hepatocytes (as intact cells) to bind specifically ,25I-labeled major 
HBsAg was not unique to this cell type. In the present study we have shown that human 
fibroblasts and human blood mononuclear cells are also able to bind major HBsAg. The 
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specific binding of major HBsAg to HepG2A16 cells (a well-differentiated human 
hepatoblastoma-derived cell line) has been demonstrated by Kaiser et al. (18). In addition, 
a receptor for the major HBsAg has also been found on Vero cells, a kidney cell line 
from the African green monkey (19). In contrast, rat hepatocytes are not able to bind 
major HBsAg. These findings indicate that the receptor specificity encoded by restricted 
regions of the virus surface structure may indeed determine the virus host range and 
tissue trophism. Nevertheless, detailed studies of the features of cell receptors and the 
corresponding virus binding sites remain to be done. 
Acknowledgement: We thank Mrs. H.M.J. Roelofs for her technical assistance. 
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ABSTRACT 
It has been suggested in the literature that the initial event of hepatitis В virus 
infection involves binding of an epitope within the preSl fragment of large HBsAg to 
a specific receptor molecule or molecules on the cell surface of human hepatocytes. 
However, no direct biochemical evidence for the existence of such a receptor was 
obtained so far. 
Previously we demonstrated that small HBsAg specifically binds to intact human 
hepatocytes, although a specific binding between large HBsAg and plasma membrane 
vesicles was also found. 
In this chapter, evidence is presented that a hepatic membrane protein with an 
apparent molecular weight of 34 kD is responsible for the specific binding of small 
HBsAg. This binding is Ca2+-dependent. The 34 kD protein also binds efficiently to 
large HBsAg, but the preSl region appears to be not involved in this binding. 
We therefore propose that one of the initial steps of HBV infection involves a specific 
binding of the S domain of the surface antigens to a 34 kD membrane protein of 
liver cells. 
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INTRODUCTION 
Hepatitis В is a major public health problem, causing over 2 million deaths annually (21). 
The hepatitis В virus (HBV) is a member of the hepadna viruses which also include the 
ground squirrel-, the tree squirrel-, the duck- and the woodchuck hepatitis viruses (S). 
These viruses share similarities in the genomic organization and viral structure (22). 
The hepatitis В virion or Dane particle consists of a 27 nm core which is encoated by 
surface antigen (HBsAg). HBsAg is the product of the S-open reading frame, containing a 
preSl, a preS2 and an S segment. This open reading frame contains three ATG initiation 
codons for protein synthesis. The most downstream situated initiation site generates the 
small HBsAg with a length of 226 amino acids. The second ATG codon initiates the 
production of surface antigen with an N-terminal extension of 55 amino acids, known as 
the preS2 region, thus yielding middle HBsAg. The third and most upstream ATG 
initiates the production of surface antigen with an additional extension of 108-119 amino 
acids, known as the preSl region, to yield the large HBs antigen. This large HBsAg 
therefore contains the preSl, preS2 and S antigenic determinants. 
Although HBV DNA and antigens have been found in various extrahepatic tissues (4), 
viral replication predominantly takes place in the liver. In addition, hepatitis В virus 
infection is a host specific event. The mechanisms that may affect the host and tissue 
tropism of the virus are not yet fully understood although progress is being made in this 
field. The existence of specific receptors often play a key role in viral tropism (10). In 
chapter 2 we demonstrated that small HBsAg binds specifically to intact human hepato-
cytes. In this chapter we describe that the specific binding of small HBsAg to plasma 
membranes of human hepatocytes is mediated by a 34 kD protein. The S sequences in 
large HBsAg are also recognized by this protein. This p34 can be detected by a HBsAg-
binding assay in human liver membrane extracts, but not in rat liver membrane extracts, 
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indicating a putative role in host tropism. This HBsAg binding protein might therefore 
play a role in the attachment of HBV to human hepatocytes as an initial step of viral 
infection. 
MATERIALS AND METHODS 
Isolation of plasma membrane vesicles (PMV) 
Human liver tissues were obtained from post mortem organ donors with informed consent 
of the family and approval by the Medical Ethical Committee for human expérimen-
tations. Tissues were cut to pieces, snap frozen in liquid nitrogen and stored at -80°C 
until use. Plasma membrane vesicles from these tissues and from rat liver were prepared 
by a modification of the method of Hubbard et al. (7) as described previously (9). This 
method yields membranes, enriched in sinusoidal fraction. 
Extraction of plasma membrane proteins 
Proteins were extracted from liver plasma membranes using the nondenaruring detergent 
CHAPS (3-[(3-cholamidopropyl) dimethyl-ammonio]-l-propanesulfonate, Boehringer, 
Mannheim, Germany). Plasma membranes were solubilized in CHAPS buffer (10 mM 
CHAPS in 0.1 M KjPO«, pH 7.2, 20% glycerol) by incubation at room temperature for 
30 min. The suspension was centrifuged for 10 min at 12,000xg to remove insoluble 
material. Supernatant was dialysed extensively against distilled water and lyophilized 
thereafter and protein concentrations were measured by the method of Lowry (11). 
Radio-labelling of proteins 
5 μg of CHAPS-solubilized membrane proteins was labelled with Ш І using Iodogen 
(l,3,4,6-tetrachloro-3a,6a diphenyl-glycouril, Pierce) according to the method of 
Salacinsky (19). After labelling, free 1 2 JI was removed by passing the reaction mixture 
over a Sephadex G25 column (Pharmacia, Uppsala, Sweden). Trichloroacetic acid (TCA) 
precipitable radioactivity was more than 85% in all experiments. The specific activity of 
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labelled proteins was always about 2xl07 cpm^μg protein. 
Binding of radio-labelled membrane proteins to HBsAg 
1 /ig of major HBsAg or equimolar amounts of middle or large HBsAg, preSl Met-110-
Gln peptide, synthetic preS2 1-55 (ay) (a kind gift of Dr. Miller, M.S.D. Lab, Westpoint, 
PA) or bovine serum albumin (BSA, Boehringer, Mannheim, Germany) as a control 
protein was coated on high binding capacity microtitre dishes (Greiner, Germany). The 
wells were left to dry at room temperature (RT) overnight. After washing with phosphate 
buffered saline containing 0.05% Tween-20 (PBS/Tween) the wells were incubated for 2 
hrs at RT with PBS/3% gelatine to minimize non specific binding. After washing with 
PBS/Tween and once with PBS to remove Tween-20, the wells were incubated for 2 hrs 
at RT with PBS/2 mM СаСУ2 mM MgCl, containing 500,000 to 1,000,000 cpm of 
radio-labelled membrane proteins. Non bound proteins were removed by washing with 
PBS/CaCl2/MgCl2 until no further radioactivity was released. Bound proteins were 
subsequently released in SDS-PAGE sample buffer and separated on 10% Polyacrylamide 
gels. After fixing and drying the gels, they were autoradiographed for 1 to 4 weeks. 
Inhibition experiments involved addition of at least lOx molar excess HBsAg or BSA as a 
negative control to the radiolabelled membrane proteins. 
RESULTS 
To examine whether one or more membrane proteins from human liver is (are) able to 
bind specifically to major HBsAg, we performed binding studies using radio-labelled 
plasma membrane proteins and recombinant major HBsAg, immobilized on high binding 
capacity microtitre plates. After extensive washing, bound proteins were released and 
subjected to gel electrophoresis and autoradiography. 
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Figure 3.1 a) Autoradiograph of SDS-PAGE analysis of radiolabelled, CHAPS extracted liver 
plasma membrane proteins, bound to small HBsAg (lanes 1-4) and to BSA (lanes 5-6), im-
mobilized on high binding capacity ELISA dishes. '"¡-labelled human liver plasma membranes 
(lanes 1-2 and 5-6) or '"¡-labeled rat liver plasma membrane proteins (lanes 3-4) were used in 
binding experiments in the absence (lanes 1,3,5) or in the presence (lanes 2,4,6) of excess 
unlabeled corresponding liver plasma membrane proteins, b) Ca2*-and Mg2*-dependence of p34 
binding to immobilized recombinant small HBsAg. Incubation buffers were PBS (lane 1), PBS with 
Co2" (lane 2), PBS with Mg2* (lane 3) and PBS with Co2* and Mg2*. 
As shown in Figure 3.1a, a single human liver plasma membrane protein binds to major 
HBsAg (lane 1). Furthermore, no binding was observed when BSA (1 ^g) was coated 
instead of major HBsAg (lane S), or when radiolabelled rat liver plasma membranes were 
used instead of human liver plasma membranes (lane 3). The same pattern of binding was 
also observed when plasma derived HBsAg (a kind gift of P.N. Lelie, Central Laboratory 
of the Dutch Red Cross Blood Transfusion Service, Amsterdam, the Netherlands) was 
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used instead of recombinant small HBsAg (data not shown). In addition, this binding can 
be abolished in the presence of excess unlabelled liver plasma membrane proteins 
(4 μg/ml) or in the presence of excess soluble HBsAg (4 μg/ml) but not by the presence 
of various controls as asialofetuin (Sigma, St Louis, M.O., USA, 4 μg/ml) or IgA 
(4 μg/ml) (fig 3.3). Therefore, this protein with an apparent molecular weight of 34 kD 
can be considered as a specific human protein that binds to small HBsAg. 
Figure 3.2 Binding of radio- А В С D 
labeled p34 to equimolar amounts 
of immobilized recombinant small 
HBsAg (lane A), recombinant 
large HBsAg (lane B), synthetic 
preSl peptide (lane C) and BSA 
as a negative control protein 
(lane D). 
Receptor-ligand interactions 
are often strictly dependent on 
the presence of Ca2+ (16). To 
test whether this is also the 
case for the interaction bet- 3 4 kD"**- Ш Р щ 
ween HBsAg and p34, we per­
formed additional binding stu­
dies in the absence of Ca2+ 
and / or Mg2+. The results are 
shown in figure 3.1b. Both in 
the absence of Ca2+ and Mg2+ (lane 1) or in the presence of only Mg2+ (lane 3) in the 
incubations, no binding of p34 to small HBsAg was observed. Only when Ca2+ is added, 
p34 is found to bind HBsAg. Addition of Mg2+ reduces the background binding of p34 
significantly. Therefore, in further experiments the presence of 2 mM of both salts was used. 
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Figure 3.3 Inhibition of p34-HBsAg binding by 
HPM (lane 2), IgA (lane 3) and ASF (lane 4). 
Lane 1: control 
Previously we described that small HBsAg 
was able to bind specifically to human 
hepatocytes, and this binding could be 
inhibited by recombinant middle protein 
(preS2+S), but not by recombinant large 
HBsAg (preSl+preS2+S). Moreover, no 
binding could be demonstrated in our 
system between large HBsAg and human 
hepatocytes. However, large HBsAg 
bound specifically to plasma membranes 
derived from human liver tissues, sugges­
ting the existence of different binding sites 
for major and large HBsAg. The binding 
between plasma membranes and radio-
labelled recombinant large HBsAg could 
be inhibited for 60% by the small HBsAg and for approximately 20% by synthetic preSl 
peptide but not by a synthetic preS2 peptide (9). To investigate whether the 34 Ш protein 
identified above could also bind to recombinant large HBsAg, we performed binding 
experiments using equimolar amounts of major HBsAg, large HBsAg, synthetic preSl 
peptide and BSA as a control protein, coated on high binding microtitre plates. p34 binds 
equally well to recombinant major and middle HBsAg. Excess of major or middle HBsAg 
or unlabelled plasma membrane proteins in the binding assay inhibits this binding 
completely (data not shown). As is demonstrated in figure 3.2, a more profound binding 
was observed between p34 and large HBsAg than between p34 and small HBsAg. Laser 
densitometry revealed that approximately twice as much p34 binds to an equimolar 
amount of large HBsAg as compared to small or middle HBsAg. There was no significant 
binding of p34 to preSl (lanes 3), nor was preSl peptide capable of inhibiting the binding 
of p34 to large HBsAg (data not shown). 
Figure 3.3 shows the results of a competition assay in which human plasma membrane 
proteins (HPM), immunoglobulin A (IgA), or asialofetuin (ASF) were added in a standard 
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assay. Only HPM inhibited binding of p34 to HBsAg, excluding the possibility that ASF 
nor IgA nor their respective ligands are involved in this binding. 
DISCUSSION 
In a previous study we have demonstrated that small HBsAg, in contrast to large HBsAg, 
binds specifically to isolated intact human hepatocytes (Kd=l pM; 50,000 binding sites 
per cell). We also found that small as well as large HBsAg binds specifically to plasma 
membrane vesicles (9). Therefore we proposed that small HBsAg is responsible for 
binding of the hepatitis В virus to the outer surface of the hepatocyte. In addition, we 
suggested that large HBsAg might bind to an "intracellular receptor", which might play a 
role in secretion of subviral or viral particles. 
In order to further characterize the binding protein(s) of HBsAg on human hepatocytes, 
which are probably responsible for viral adherence and infection, we investigated the 
possible existence of a small HBsAg binding protein in binding studies using immobilized 
HBsAg and radiolabelled plasma membrane proteins, isolated from human liver. Here we 
report the presence of a 34 Kd HBsAg binding protein (p34) which is present specifically 
in human liver plasma membranes and not in rat liver plasma membranes. This protein 
binds specifically to small, middle and large HBsAg but not to BSA. 
Since the preSl region of large HBsAg is immunologically cross-reactive with im­
munoglobulin A (IgA, 13), it has been suggested that hepatitis В virus uses the IgA 
receptor to enter the liver cell. It has also been postulated in another report that the 
asialoglycoprotein receptor (ASGPR) might act as a receptor for HBV. To test whether 
these membrane proteins are involved in HBV binding, we performed our binding assay 
in the presence of excess IgA and asialofetuin, which is a ligand for the asialoglyco­
protein receptor. Neither of these ligands were able to inhibit the binding of p34 to 
HBsAg, indicating that p34 is not related to the IgA receptor or ASGPR. 
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As is the case for various receptor-ligand interactions, the binding of p34 to HBsAg is 
strictly Ca++-dependent. Addition of Mg++ to the incubation increased the binding 
specificity; the background binding was remarkably reduced as compared to the in-
cubation with Ca** alone. 
In our binding assay, large HBsAg binds approximately twice as much receptor protein as 
small and middle HBsAg. This difference in affinity can not be explained by an additional 
binding site on p34 for the preSl region of large HBsAg, because 
a) solid-phase coated synthetic preSl does not bind any p34 and 
b) synthetic preSl does not decrease the binding of radiolabelled p34 to large HBsAg. 
The binding of large HBsAg to p34 must therefore be mediated by the small S sequence. 
One explanation for the difference in p34-binding efficiency between large and small 
HBsAg might be the following: 
The presence of the preSl region in large HBsAg might cause changes in the 
secondary and/or tertiary structure of the S-domain, leading to an increased affinity 
for p34. Bearing in mind that large HBsAg only binds to intracellular membranes or 
to the inner side of the plasma membrane (9), this increase in affinity applies only to 
intracellular p34. The fact that preSl increases the binding of large HBsAg to 
intracellular p34, but completely inhibits its binding to extracellular p34 seems 
contradictory but can be explained: 
P34 apparently is a membrane protein, because it is found in isolated membrane 
vesicles. In general, membrane proteins are subjected to extensive post-translational 
processing (e.g. cleavage of signal sequences, glycosylates). Secondary and tertiary 
structures of one and the same protein might therefore differ, depending on its 
localization in the cell. Obviously these differences might have a profound effect on 
the binding of a ligand. 
In chapter 2 we demonstrated that the binding of large HBsAg to human liver membrane 
vesicles could be inhibited by small HBsAg (60%) and by synthetic preSl peptide (20%). 
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In our in vitro binding assay we could not demonstrate an involvement of preSl in the 
large HBsAg-p34 interaction. There are two possible explanations for this apparent 
controversy: 
- PreSl binds to an intracellular receptor that is distinct from p34 and which presence 
can not be demonstrated in our system. 
- P34 looses its ability to bind preSl following solubilization with CHAPS. In that case 
the putative preSl binding site on p34 would be formed by interaction of p34 with 
phospholipids in the membrane. 
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ABSTRACT 
Small envelope protein particles (plasma derived and recombinant) of the hepatitis В 
virus bind specifically to a human liver plasma membrane protein (34 kDa fraction). 
This protein was purified by two dimensional gel electrophoresis and was identified 
by co-electrophoresis of radiolabeled binding protein and by partial sequencing, as 
endonexin П, a member of the family of Ca2+-dependent phospholipid-binding 
proteins known as annexins. Despite the distribution and high degree of amino acid 
sequence similarity of this protein in a wide variety of tissues and species, the 
binding of small HBsAg particles to human liver endonexin Π is quite unique. 
Although the biological relevance is not clear yet, the specific binding property of 
small HBsAg to human liver endonexin Π is further evidenced by the finding of 
spontaneous development of anti-idiotypic antibodies (Ab2, anti-HBs) in all rabbits 
that were Immunized with native or recombinant human liver endonexin Π. Never­
theless, demonstration that human liver endonexin Π is involved in infection of 
hepatitis В virus remains to be established. 
Hepatitis В virus (HBV) infection is a major infectious disease and specifically causes 
liver disorder. It is estimated that more than 200 million people worldwide are infected 
with this virus. Although tremendous progress has been achieved in the two last decades 
in hepatitis В research, the mechanisms of infection at the cellular level are still unknown. 
The observation that hepatitis В virus (HBV) infection has a significant hepatotropism and 
species specificity (1-3), suggests that HBV recognizes specific molecules on the surface 
of the human hepatocyte and that the viral envelope proteins might play an important role 
in recognizing these molecules. Indeed, it has been reported that the preSl-region (AA 
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residues 21-47) of large HBsAg contains an attachment site for plasma membranes, 
derived from hepatoblastoma cell line HepG2 as well as from human liver tissue (4-6). 
However, no direct biochemical evidence for the existence of such preSl-binding protein 
was obtained so far. It has also been found that middle HBsAg binds specifically to 
polymerized human serum albumin (pHSA), within the preS2-region (7-9). Furthermore, 
pHSA binds to hepatocytes, although this binding is not species specific. In recent years, 
however, the importance of pHSA binding was questioned by the observation that pHSA 
was only able to bind if it was cross-linked by glutaraldehyde (10) or transglutaminase 
(11). In a previous study, we found that small HBsAg was able to bind specifically to 
human hepatocytes, human fibroblasts and human blood mononuclear cells (12). This 
finding supports the assumption that HBV attachment to human hepatocytes is mediated 
by specific proteins, recognizing an amino acid sequence in the S region. 
In order to identify human liver plasma membrane protein(s), that could bind specifically 
to small HBsAg, the following binding experiments were performed. Wells of high bond 
ELISA dishes were coated with 1 /ig of recombinant small HBsAg (13,14) or bovine 
serum albumin (BSA) in phosphate buffered saline (PBS). After washing with PBS 
containing 0.05% Tween-20 (PBS/Tween), the wells were incubated for 2 hours at room 
temperature (RT) with PBS/3% gelatin to reduce non-specific binding. After subsequent 
washing, the wells were incubated for 2 hours at RT with PBS/2 mM Ca2+/2 roM Mg2+ 
containing 500,000 to 1,000,000 cpm radiolabeled plasma membrane proteins. These liver 
plasma membrane proteins were extracted from human or rat liver plasma membrane 
preparations, using the non-denaturing detergent CHAPS (3-[3-cholamidopropyl)dimethyl 
ammonio]-l-propane-sulfonate)(Bio-Rad, Richmond, California, USA), as described 
previously (12) and were subsequently labeled with 1.37x10* Bq NaI25I (Amersham, 
Buckinghamshire, England) according to the method of Salicinski et al. (15). 
After 2 hours of incubation, non-bound proteins were removed by intensive washing with 
PBS/Ca2+/Mg2+. Bound proteins were released in SDS-PAGE sample buffer and sepa­
rated by 10% Polyacrylamide gel electrophoresis (PAGE). After fixing and drying, the 
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Figure 4.1 Autoradiograph of SDS-PAGE analysis of human liver plasma membrane proteins 
bound to recombinant small HBsAg (lanes 1-4) and to BSA (lanes 5-6), immobilized on high bond 
ELISA dishes. '^¡-labeled human liver plasma membrane proteins (lanes 1-2 and 5-6) or ,2SI-
labeled rat liver plasma membrane proteins (lanes 3-4) were used in these binding experiments in 
the absence (lanes 1,3,5) or in the presence of excess unlabeled corresponding liver plasma 
membrane proteins (lanes 2,4,6). 
gel was autoradiographed. As shown in figure 4.1, a single human liver plasma 
membrane protein, with an apparent MW of 34 kD (p34), was found to bind specifically 
to small HBsAg in a Ca2+-dependent manner (see also figure 3.1). In parallel binding 
experiments using rat liver plasma membrane proteins and recombinant small HBsAg, or 
human liver plasma membrane proteins and BSA on solid phase, no proteins were found 
to bind to solid phase. 
To obtain a sufficient amount of this small HBsAg-binding protein for amino acid 
sequence analysis, radio-labeled small HBsAg binding protein (p34) from human liver 
82 
CHAPTER 4: HBsAg BINDING PROPERTIES OF HUMAN ENDONEXIN Π 
plasma membranes obtained from binding assays as described in figure 4.1 was mixed 
with a 34 kD fraction of human liver plasma membrane proteins, isolated by preparative 
gel electrophoresis, and subjected to two-dimensional (2D) gel electrophoresis. Prior to 
2D gel electrophoresis, the isolated 34 kD protein fraction was concentrated by vacuum 
centrifugation in a Savant speedvac or by Centriprep filtration (cut-off: 10 kD; Amicon 
Division W.R. Grace & Co., Conn. Beverly, MA, USA), precipitated overnight (4°C) 
with trichloroacetic acid (TCA) (20% w/v final concentration) and washed with 20% 
TCA, acetone and acetone containing 1% (v/v) triethylamine. The sample was dried 
under reduced pressure and dissolved in no more than 200 μΐ lysis buffer (9.5 M urea, 
5% 2-mercaptoethanol, 2% CHAPS and 5% Resolyte pH 3.5-10 (Hoefer, San Fransisco, 
CA, USA). The first dimension of 2D gel electrophoresis was performed on ultrathin (0.5 
mm) Polyacrylamide gels coated on to PAG-Gelbond film (FMC, Rockland, ME, USA) 
and with a pH gradient built up by a mixture (3:1) of Pharmalyte pH 2.5-5 (Pharmacia) 
and Resolyte pH 4-8 (Hoefer). 
Electrophoresis in the second dimension was carried out in a 10% Tricine gel (16). Co-
migration of labeled and non-labeled material resulted in a Coomassie Brilliant Blue 
(CBB) stainable spot, corresponding with a single radioactive spot of protein with an 
apparent molecular weight of 34 kD and a pi of 4.1 (figure 4.2a (arrow) and 4.2b). 
A sequenceable amount of p34 protein (estimated at 4 μ%) was obtained by excision of 50 
CBB-stained gels, rerun in a concentration device gel (17) and submitted to in situ limited 
acid hydrolysis (18). The generated peptides were separated by reversed phase high 
pressure liquid chromatography (HPLC, figure 4.3). Partial amino acid sequences of 
internal peptides (table 4.1) and subsequent screening against the Swiss protein databank 
(Department of Medical Biochemistry of University of Geneva and EMBL data libraries) 
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Figure 4,2 a) Two dimensional gel electrophoresis of a 34 kD protein fraction, isolated by 
preparative PAGE, of human liver plasma membrane proteins. The relatively acidic protein, with 
pi 4.1 (arrow) has been identified as the small HBsAg binding protein by superimposing figure 
4.2b on figure 4.2a. The proteins were analysed by iso-electric focusing (IEF)ZSDS-PAGE based 
on the system ofO'Farrel (28) with minor modifications as described by Meheus et al. (29). 
b) Autoradiograph of IEF/SDS-PAGE analysis of eluted l2SI-labeled human liver plasma membrane 
protein, bound to small HBsAg, immobilized on high bond ELISA dishes as described in figure 
4.1. The single spot on the figure corresponds to a protein with a MW of 34 kD and a pi of 4.1 
(see also figure 4.2a) 
Tabel 4.1 (page 85) Amino acid sequences of peptides, found in reversed phase H PLC fractions, 
were determined using a pulsed liquid model 477A Sequenator (Applied Biosystems) equipped with 
an on-line 120 phenylthiohydantoine analyser (Applied Biosystems). The amino acids between 
parenthesis gave no clear signal in their analysis, while asterisks indicate no signal was obtained 
for this residue. 
Amino acid sequences, found as illustrated in this table, were then used for screening against the 
Swiss protein databank (Department of Medical Biochemistry of the University of Geneva and 
EMBL data libraries) and resulted in the identification ofp34 as Endonexin ¡I. 
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Figure 4.3 Reversed phase HPLC pattern of peptides, generated after limited acid hydrolysis 
ofp34. Peaks 5, 21, 24, 25 and 42 were used for sequence analysis. 
Table 4.1 
fraction AHS 
fraction AH21 
fraction AH24a 
fraction AH24b 
fraction AH24c 
fraction AH2S 
fraction AH42 
AlaGluThrLeuArgLysAlaMetLysGlyLeu 
TyrLysLysAlaLeuLeuLeuLeu(Gln)GlyGlu 
AlaGlnAlaLeuPheGlnAlaGlyGluLeu* 
TyrLysLysAlaLeuLeuLeuLeu'GlyGluAsp 
ThrSerGlyAspTyrLysLysAlaLeuLeuLeuLeu*GlyGluAsp 
****PheGlnAlaGlyGluLeu(Lys)*Gly 
AlaTyrGluLeuLys(Gln)AlaLeuLysGlyAlaGlyThrAsnGluLys 
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revealed the identification of p34 as Endonexin II (E-II). Comparison of amino acid and 
cDNA sequences of E-II cDNA clones, obtained by sequence analysis of E-II cDNA 
clones isolated from a human liver cDNA library, showed a complete sequence identity 
with those of human placental E-II, as reported by Kaplan et al. (19). 
MW(kD) 
8 4 -
5 0 -
2 7 -
Figure 4.4 Autoradiograph ofSDS-PAGE analysis of human liver E-II bound to recombinant small 
HBsAg, immobilized on high bond ELISA dishes in the absence or presence of competitors. 12SI-
labeled human liver E-II (approximately 150,000 cpm) was used in the absence (lane I) or in the 
presence (lane 2) of excess unlabeled E-II and, in other experiments, in the presence of excess 
recombinant small HBsAg (lane 3), or excess unlabeled human liver plasma membrane proteins 
(lane 4). Pre-incubation of labeled E-II with rabbit anti-E-II serum (1:200) inhibits the binding oj 
E-II to small HBsAg (lane 5), while pre-incubation with preimmune serum does not (lane 6). 
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To further characterize the specificity of binding properties of Ε-Π to small HBsAg, 
binding experiments were repeated with purified native Ε-Π, prepared from human liver 
tissue according to the method of Haigler et al. (20). Ε-Π isolated by this method 
(Sephadex G-100 and DE-52 ion-exchange column chromatography), was found to be a 
single spot on two dimensional gel electrophoresis. As shown in figure 4.4, binding of 
radiolabeled Ε-Π to small HBsAg can be inhibited by the presence of excess unlabeled Ε-
Π, excess unlabeled human liver plasma membrane proteins or the presence of excess 
unlabeled small HBsAg, but not by the presence of excess unlabeled rat liver plasma 
membrane proteins or purified native rat liver E-II (data not shown). Furthermore rabbit 
anti-human liver E-II specific antiserum blocks the binding of radiolabeled Ε-Π to small 
HBsAg (figure 4.4). In addition, when the chemical cross-linker disuccinimidyl suberate 
(DSS) (Pierce, Rockford, IL, USA) was added in binding experiments between radio­
labeled Ε-Π and small HBsAg, an additional protein complex with an apparent molecular 
weight of 90 kD appeared on SDS-PAGE and no such band was observed when reactions 
were performed between radiolabeled E-II and asialofetuin (ASF) or BSA (figure 4.5). 
Cross-linking was performed by addition of a solution of 50 mM DSS in dimethylsul-
foxide (DMSO) to a final concentration of 1 mM to the mixture of proteins. The reaction 
was allowed to proceed for 30 minutes at 4°C and was stopped by adding 1 M glycine to 
a final concentration of 100 mM. Although only a small fraction of human liver Ε-Π is 
observed to be cross-linked with HBsAg, such a finding is not unusual for a cross-linking 
experiment as has been shown for somatostatin-14 binding protein (21), IL-1 and IL-6 
receptor (22,23) to their respective ligands. The possible presence of a contaminant in the 
recombinant and plasma derived HBsAg preparations was excluded by the absence of 
additional bands on PAGE following silver staining, and by a complete immuno-
precipitation of radiolabeled HBsAg with anti-HBs specific antibodies (data not shown). 
Thus this protein complex is very likely to be the result of an interaction between one 
molecule human liver Ε-Π with two molecules of small HBsAg or between two molecules 
of human liver Ε-Π with one molecule of small HBsAg. Based on these findings of 
competitive binding- and cross-linking experiments, the binding properties of small 
HBsAg to Ε-Π seems to be specific and unique. However, endonexin Π (also known as 
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Figure 4.5 Left panel. SDS-PAGE analysis of cross-linking experiments between 12¡I-labeled E-II 
and solid phase recombinant or serum derived small HBsAg. Cross-linking of E-II to recombinant 
(lane 3) or serum derived (lane 4) small HBsAg in the presence of DSS resulted in a labeled 
complex with a molecular weight of approximately 90 kD. Lane 1 (recombinant HBsAg) and lane 
2 (serum-derived HBsAg) represent control experiments, without cross-linker. 
Right panel. SDS-PAGE analysis of radiolabeled E-II in cross-linking experiments in solution, with 
E-II (lane 1), BSA (lane 3), Asialofetuin (lane 4) or HBsAg (lane 2). Only in the experiment with 
HBsAg, an additional band with an apparent MW of 90 kD was observed on SDS-PAGE. 
annexin V) is a member of the family of Ca2+-dependent phospholipid-binding proteins 
known as annexins. Phospholipids are also known to be an important component of 
HBsAg lipoprotein particles (both serum-derived and recombinant HBsAg) and the present 
binding may simply reflect this lipid association. In fact, the Ca2+-dependence of the 
HBsAg binding can possibly reflect the known Ca2+ requirement of annexins for 
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phospholipid binding and might therefore be entirely consistent with this possiblity. In this 
regard, it is important and interesting to note that despite the distribution and amino acid 
sequence similarity (92% sequence homology between human and rat Ε-Π) of Ε-Π in a 
wide variety of tissues and species (24), the binding of small HBsAg to human liver £-11 
is unique. No binding was observed between small HBsAg and purified rat liver E-II. 
Furthermore, no Ε-Π was found to bind to small HBsAg when binding studies were 
performed using plasma membrane proteins derived from rat liver tissue. In addition, 
binding of human liver E-II to serum derived small HBsAg (25) excludes the possibility 
of specific interaction between human liver Ε-Π with the phospholipid component derived 
from yeast cells in recombinant HBsAg lipoprotein particles. 
In order to further determine whether the binding of human liver E-II to small HBsAg is 
indeed the result of a protein-protein interaction and is highly specific as it used to be 
demonstrated by a receptor protein for its specific ligand, we have decided to investigate 
whether immunization of rabbits with endonexin II would lead to the development of anti-
idiotypic (anti-HBs) antibodies (26). Anti-HBs activity was found in all four rabbits (two 
immunized with highly purified native human liver E-II and two with purified recom­
binant human liver Ε-Π) within few weeks after immunization and following the anti-Ε-Π 
activity. The presence of anti-HBs activity in these experiments suggests three pos­
sibilities: 
The first is that the human liver E-II, used as immunogen, was contaminated with 
HBsAg. However, this possibility can be entirely excluded, since rabbits immunized with 
purified recombinant Ε-Π were also found to have anti-HBs reactivity to the same extent 
as rabbits immunized with native human liver E-II. Furthermore, in a retrospective 
investigation, the liver tissue used for isolating native E-II was found to be HBsAg 
negative in addition to a negative finding for HBsAg of the batches of E-II (recombinant 
and native) used for immunization. Moreover, the antibody raised in that case should 
react with various epitopes of HBsAg. This seems unlikely since this antibody contains 
neither anti-preSl activity, nor has an inhibitory effect on the interaction between small 
HBsAg and several anti-HBs murine monoclonal antibodies. 
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The second possibility is that this antibody could react with an epitope, shared by E-II 
and HBsAg (cross-reactivity). In order to examine this hypothesis, the anti-HBs and anti-
E-II antibodies, present in the rabbit immune serum, were affinity purified using 
recombinant Ε-Π coupled to CNBr-activated Sepharose. If anti-HBs and anti-E-II activity 
are not due to cross-reactivity, reactivity to both antigens must be found in different 
fractions after affinity chromatography. For these investigations, ELISA were set up to 
detect antibodies separately using 100 ng of each antigen immobilized on high bond 
ELISA dishes by overnight incubation at 4°C. After blocking non-specific binding sites, 
by incubating the wells with PBS/Blotto l%/Tween-20 0.05%, wells were incubated with 
a 1:50 dilution of the isolated fractions, followed by incubation with peroxidase con­
jugated swine anti-rabbit antiserum (Dakopatts A/S, Glostrup, Denmark). Staining was 
performed with tetramethylbenzidine (TMB) (Boehringer-Mannheim, Germany) in the 
presence of hydrogen peroxide and optical densities were measured at 450 nm. 
As demonstrated in figure 4.6, the anti-HBs activity can be separated from antibody 
activity to E-II, indicating that the anti-HBs response is not due to cross-reactivity. 
The final hypothesis is that the anti-HBs antibody could be a spontaneously generated 
anti-idiotypic antibody (Ab2) that reacts with a site on small HBsAg that binds human 
liver Ε-Π, as has also been recently described for vinculin and talin showing a receptor-
ligand relationship (27). In this case, human liver Ε-Π should be able to compete with the 
anti-HBs antibody, isolated from the rabbit immune serum, for the Ε-Π binding site on 
small HBsAg. For these experiments, high bond ELISA dishes were coated with 500 ng 
of antibodies purified by Protein A and subsequent E-II column chromatography (see 
figure 4.6), followed by incubation with PBS/gelatin 3% to block non-specific binding 
sites and washing with PBS/Tween. In the first experiment (fig 4.7, o—o) wells were then 
incubated with a serial dilution of unlabeled HBsAg (highest concentration: 200 ng/well) 
and subsequently, radiolabeled HBsAg (30 ng) was added. In the second experiment 
(·—·), wells were incubated with previously prepared mixtures of 30 ng radiolabeled 
HBsAg and serial dilutions of E-II and 1 mM Ca2+ and Mg2+ (highest concentration: 
50 ng/well). After incubation for 1 hour at room temperature, wells were washed inten-
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sively with PBS/Tween. Bound HBsAg was released in SDS-PAGE sample buffer and 
transferred to counting tubes. As shown in figure 4.7, human liver E-II succesfully 
competes with the anti-HBs antibody for binding to small HBsAg. It is therefore 
concluded that the observed anti-HBs antibody is an anti-idiotypic antibody, which mimics 
a region of E-II that interacts with small HBsAg. From experimental animals, immunized 
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Figure 4.6 Separation of antibodies, reacting with small HBsAg or E-II, by affinity 
chromatography on purified recombinant E-II, coupled to CNBr-activated Sepharose (Pharmacia, 
Uppsala, Sweden). As starting material for the discriminative affinity chromatography, a batch q¡ 
polyclonal antibodies with anti-HBs activity, obtained from a rabbit immunized with purifiée 
human liver E-II, was purified by Protein A Sepharose column chromatography. The resulting IgC 
protein (5 mg) was subsequently applied to an affinity column prepared by the coupling of purifiée 
recombinant E-II to CNBr-activated Sepharose. Bound antibodies were recovered by washing tht 
column with 4.5 M MgQ^ Flow-through fractions (fractions 1-12) as well as eluted fraction, 
(fractions 13-18) were collected and examined for their reactivity towards small HBsAg and E-II. 
Anti-HBs reactivity (o—o) was predominantly found in the flow-through fractions (1-6), while anti 
E-II reactivity (*-*) was exclusively found in the eluted fractions (fractions 14-17). 
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Figure 4.7 Competition between radiolabeled and unlabeled HBsAg for binding to anti-
idiotypic antibodies and between anti-idiotypic antibodies and human liver E-II for 
binding to radiolabeled HBsAg. Pre-incubation of anti-idiotypic antibodies on solid phase 
with serial dilutions of unlabeled HBsAg (o—o) prevents binding of radiolabeled HBsAg 
(cpm) to the anti-idiotypic antibody. When radiolabeled HBsAg is рте-incubated with 
serial dilutions of E-II (*--*) in the presence of Ca2* and Mg1*, a comparable inhibition 
for binding of radiolabeled HBsAg (cpm) to the anti-idiotypic antibody, was observed. 
Average cpm, bound in control experiments, are represented by (ét). 
with human liver E-II, such anti-idiotypic antibodies can only be generated if human livei 
Е-П and small HBsAg have such interacting binding sites, showing the receptor-ligand 
relationship. 
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While evidence accumulated to support the existence of a specific binding between 
hepatitis В virus small envelope protein and a human liver cell protein identified as 
endonexin П, the biological relevance of this finding remains unclear. Although the 
binding of HBsAg to intact human hepatocytes can be specifically inhibited by this protein 
and by anti-idiotypic antibodies (Ab2), and not by rat liver endonexin II (data not shown), 
demonstration that human liver E-II is involved in infection would require that the protein 
could be used to block infection, that antibody to the protein blocks infection, or that 
expression of the protein in permissive but non-susceptible cells renders infectability to 
these cells. 
These studies are currently in progress. 
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SUMMARY 
Human hepatocytes contain protein molecules on their surface that bind to the 
human hepatitis В virus (HBV) surface protein. This hepatocellular protein was 
previously Identified as endonexin П, a Ca1+-dependent phospholipid binding protein 
of 34 kilodaltons. A full length cDNA clone, encoding human endonexin Π was 
isolated from a human liver cDNA library and was placed under the control of the 
polyhedrin promoter of Autographa californica nuclear polyhedrosis virus (AcNPV). 
The resulting recombinant virus yielded high amounts of recombinant protein after 
Infection of Spodoptera frugiperda cells. This protein has the same molecular weight 
and iso-electric point as native human endonexin Π. It can be easily purified by 
methods, analogous to those described for the native protein. Moreover, the recom­
binant product binds very efficiently to hepatitis В surface proteins (HBsAg) in a 
similar fashion as native human endonexin П. 
INTRODUCTION 
Hepatitis В is still a major world health problem. Its manifestations are numerous and the 
chronic form of hepatitis В is unequivocally responsible for liver cirrhosis and hepatocel­
lular carcinoma, resulting in significant mortality (21,22). 
Although a great deal is known about the structure of the virus, its genome and the 
regulatory elements involved in viral DNA transcription (10,20), not much is known 
about the way HBV enters the liver cell. One of the main causes for this lack of 
knowledge is the inability of the virus to infect in vitro cells, other than human or certain 
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primate liver cells. This strict host- and tissue specificity of HBV has been the subject of 
extensive investigation. 
It has been shown that tissue specificity is caused by the need for liver specific factors by 
the various viral promoters and enhancers to act properly (2,26,27). An obvious cause for 
host and tissue tropism might also be the existence of a specific cellular receptor for the 
virion, enabling it to enter the liver cell. The existence of specific receptors for viruses is 
not unknown in virology (24). A receptor can even be the sole determinant for viral 
tropism. Therefore, one possible means of vaccination or treatment of viral hepatitis В 
could be the prevention of the virus from entering the liver cell by blocking the interac­
tion between virus and cellular receptor. 
The localization of the receptor binding site on the hepatitis В surface protein (HBsAg) 
has been the subject of a lot of discussion in the literature. A receptor for the preSl 
region of the hepatitis В large HBsAg is thought to exist on human liver cell membranes 
and certain liver derived cell lines (11,15,19). It was concluded that the virus particle 
binds via its preSl sequences to human hepatocytes. However, we have been unable to 
demonstrate the existence of preSl receptors on intact isolated human hepatocytes (11). In 
contrast, a specific binding of major HBsAg to intact human liver cells was demon­
strable. 
Recently we identified the major HBsAg binding protein on human liver cells as en-
donexin Π (S). Human endonexin II belongs to the family of annexins, a group of closely 
related and highly conserved Ca2+-dependent phospholipid-binding proteins with 
molecular weights ranging from 32-67 kilodaltons (8). 
To investigate the usefulness of endonexin II as a therapeutic agent, and to be able to 
conduct research to localize the exact binding epitopes on the viral surface proteins and 
on the receptor itself, large amounts of purified protein are generally required. To achieve 
this, we isolated endonexin II cDNA from a human liver cDNA library. This cDNA was 
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cloned in the well characterized baculovirus expression system (12,18). The recombinant 
protein is produced in high amounts, is easy to purify and binds efficiently to HBsAg. 
We consider this recombinant protein to be a very important tool in future hepatitis В 
research. 
MATERIALS AND METHODS 
Screening ofcDNA library for endonexin И 
Using amino acid sequence information from the HBsAg binding protein (5), the 36-mer 
5'-TTTTTCATrTGTTCCAGCTCCCTTCAAGGCATGTTT-3' was synthesized on a 
Perkin Elmer DNA synthesizer. This oligonucleotide was labeled with T- J 2P-ATP using 
T4-polynucleotide kinase (Life Technologies) according to the manufacturers instructions. 
A human liver cDNA library in phage lambda-ZAP (a kind gift from dr. Lamers, 
Academical Medical Center, Amsterdam) was screened with this probe using standard 
plaque lifting and hybridization techniques. cDNA inserts were rescued from these clones 
by co-infection of E.Coli JM109 cells with the concerning recombinant phage-lambda-
ZAP and helper phage R408. Recombination events lead to the formation of the plasmid 
pBluescript, containing the cDNA inserts in the EcoRl site of its polylinker. 
DNA manipulations 
DNA manipulations were carried out essentially according to standard procedures (14). 
Restriction enzymes and other DNA-modifying enzymes were purchased from Life 
Technologies. High temperature DNA sequencing was performed using a Taq-polymerase 
based kit (Promega) according to the manufacturers instructions. Electrophoresis of the 
reaction products was performed in 7% acrylamide/7 M urea gels under standard con­
ditions (BRL SA-100 system). 
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Cells and viruses 
Spodoptera frugiperda (Sf9) cells were grown as monolayer cultures at 27°C in TC100 
medium (Gibco/BRL), supplemented with 10% fetal bovine serum (FBS) and 40 /ig/ml 
gentamycin. Seeding of the cells and subsequent virus infections were performed as 
described by Summers and Smith (23). 
Construction of baculovirus transfervectors pVLendo-1.4AE andpVLendo-1.4EE 
Figure S.l shows the strategy used for introduction of human liver endonexin Π cDNA in 
the baculovirus transfervector pVL941. 
The cDNA inserts were purified from pBluescript by digestion with EcoRl, electro­
phoresis on 0.6% agarose gels and electro-elution using a biotrap apparatus (Schleicher & 
Schuil). 116 of the ISO non-coding nucleotides at the S'-terminus (fig.l) were removed by 
digestion at a unique Avail site in the endonexin Π cDNA, 34 nucleotides upstream from 
the start codon. From this А аП-EcoRl fragment and the original EcoRl-EcoRl frag­
ment, the termini were made blunt using T4-DNA polymerase (Life Technologies) and 
the resulting blunt fragments were ligated in the dephosphorylated Smal site of 
pGEM3Zf[-] (Promega) resulting in pGEMendo-1.4AE (1.4 Kb Avall-EcoRl fragment) 
and pGEMendo-l.SEE (l.S Kb EcoRl-EcoRl fragment). The internal Hindlll restriction 
site (at nucleotide 1310) was used to select for plasmids, containing the insert in the 
correct orientation for future expression. One pGEMendo vector, containing the 1.4 Kb 
Avall-EcoRl fragment in the wrong orientation, was used to act as a negative control for 
later infection (pGEMendo-1.4EA). The pGEM-endo vectors were digested with BamHl 
and Kpnl and cDNA inserts were purified by agarose gel electrophoresis and electro-
elution. 
From the baculovirus transfer vector pVL941 a 535 bp BamHl-Kpnl polyhedrin fragment 
was removed and kept for later use in recombinant virus purification. This fragment was 
replaced by the endonexin II encoding BamHl-Kpnl fragments, purified from the 
pGEMendo plasmids, resulting in pVLendo-1.5EE, pVLendo-1.4AE and pVLendo-
1.4EA. 
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Figure 5.1 Construction of pVLendo transfervector s : IA) Endonexin Π cDNA, picked from a 
human liver cDNA library in phage lambda-ZAP, was cloned in the Smal site of plasmid 
pGEM37fl-]. Using the flanking BamHl and Kpnl restriction sites, this cDNA was cloned 
unidirectional in the BamHl/Kpnl digested baculovirus transfervector pVL941. IB) Besides the 
complete cDNA fragment, an Avall-EcoRl fragment lacking 135 5'-termlnal non-coding 
nucleotides was cloned in pVL941 in order to minimalize the distance between promoter and 
initiation codon. Nomenclature for the resulting transfervectors is: pVLendo-1.5EE (1.5 Kb 
EcoRl-EcoRl fragment in the coding orientation); pVLendo-1.4AE (1.4 Kb Avall-EcoRl fragment 
in the coding orientation); pVLendo-1.4EA (1.4 Kb Avall-EcoRl fragment in the non-coding 
orientation, serving as a control). 
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Cotransfection and purification of recombinant baculovirus 
To introduce the endonexin Π gene in the baculovirus genome, pVLendo plasmids and 
wild type Autographa californica nuclear polyhedrosis virus (AcNPV) DNA were 
cotransfected in Spodoptera frugiperda cells (SF9). 2x10* Sf9 cells were seeded in a 25 
cm
2
 culture flask (Costar). After 3 hrs, cell monolayers were washed three times with 
serum-free SF900 medium (Gibco BRL) to remove traces of FBS. 2 μg pVLendo and 1 
μg AcNPV DNA in sterile water (40 μΐ) was mixed with 40 μΐ (10 /xg) of lipofectin 
reagent (Life Technologies) and left to stand for IS min at room temperature. The 
resulting DNA-liposome complex was diluted with 2 ml SF900 medium and added 
dropwise to the cells. After overnight transfection, the cells were washed once with and 
cultured in TC100 medium, supplemented with 10% FBS and 40 /ig/ml gentamycin. 
After 5 days of culture, a 10s fold dilution of the cell culture supernatant was used to 
infect 10* Sf9 cells/well in 96 wells dishes. Again after 5 days of culture, cell super-
natants were removed and stored in sterile 96-wells dishes at 4°C. Cells were lysed in 
200 μΐ 0.5 N NaOH. After neutralization with 20 μΐ of 10 M NILOAc the lysate was spot 
on nitrocellulose filters using a dot blot apparatus. Dot blots were hybridized under 
standard conditions (14) with agarose gel purified, "P-dCTP labeled 1.4 Kb endonexin Π 
cDNA. 
Culture media from positive wells were used in a 10* fold dilution to infect Sf9 cells in 96 
wells dishes. This whole procedure was repeated three times in order to purify recom­
binant virus. Finally, medium from positive wells was used to infect 75 cm2 culture 
flasks, containing 2x10s Sf9 cells. Cells were harvested three days p.i. A fraction of the 
homogenate was lysed in NaOH, neutralized and spotted on nitrocellulose. Hybridization 
with the 535 bp BamHl-Kpnl polyhedrin gene fragment was performed to test for the 
presence of wild type AcNPV. Supernatants were used as virus stocks and stored at 4°C 
for immediate use and at -80°C for long term storage. The titer of these virus stocks was 
determined by serial dilutions in a dot blot assay. Nomenclature for the recombinant 
viruses was Acendo-l.SEE, Ac-endol.4AE and Ac-endol.4EA, according to the previous 
used nomenclature for the various plasmids. 
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Iso-electric focusing, SDS-potyacrylamidegel electrophoresis and western blotting 
To analyse recombinant cells for production of endonexin Π, cells were homogenized in 
buffer H (20 mM HEPES pH 7.4, 150 mM KCl, 2 πιΜ MgCl2, 0.1 mM phenyl-methyl-
sulfonyl fluoride) using a glass-glass Potter Elvehjem. 20 /ig of protein was boiled in 
SDS-PAGE sample buffer and proteins were electrophoresed on 10% Polyacrylamide 
gels. Semi-dry western blotting was performed on a Novablot apparatus (Pharmacia) 
under standard conditions. Immunoblots were incubated during 1 hr at room temperature 
with blocking buffer (phosphate buffered saline pH7.4, 0.05% Tween-20, 1% gelatine). 
Subsequently the blots were incubated overnight with a 1:5000 dilution of a rabbit 
antiserum, raised against highly purified human endonexin II. Bound antibodies were 
detected by a 2 hrs incubation with peroxidase-conjugated Swine anti rabbit Im­
munoglobuline (1:800, Dakopatts) and colour development in 50 mM Tris, pH7.6, 0.06% 
diaminobenzidine, 0.03% Cobalt chloride (CoClj). Iso-electric focusing was performed on 
pre-cast ampholine pH gradient gels in a Phast-System apparatus (Pharmacia, Uppsala, 
Sweden), followed by staining with Coomassie Brilliant Blue. pH markers in the range Β­
ΙΟ were purchased from the same manufacturer. 
Immunocytochemical studies on Sf9 celL·, infected with recombinant virus 
100,000 Sf9 cells were seeded in 4 wells plates (Costar) with glass cover slips and 
allowed to attach for 2 hrs. The cells were infected with wild type or recombinant virus 
with an m.o.i. of 1. Cells were washed with phosphate buffered saline (PBS) and fixed 
with ice-cold methanol at 1, 2, 3 and 4 days post infection. After drying, cells were 
stored at -20°C until analysis. Cells were thawed in ice-cold methanol and washed in 
PBS. Endogenous peroxidase activity was blocked by a 10 min incubation with 
methanol/3 %H202. Aspecific binding sites were blocked in PBSTTB (PBS containing 
0.05% Tween-20, 0.1% Triton-XlOO, 4% BSA). The cells were incubated overnight at 
4°C with a 1:1500 dilution of a polyclonal rabbit antiserum against human liver-purified 
endonexin Π in PBSTTB. After extensive washing with PBS-0.05% Tween-20, peroxidase 
conjugated swine antibody against rabbit IgG (1:40 in PBSTTB) was added. After 1 hr, 
cells were washed in PBS/0.05% Tween-20. Peroxidase was visualized by reaction with 
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0.1% diaminobenzidine in PBS with 0.3% H202 for ten minutes. Cells were counter-
stained with haematoxylin, dehydrated, mounted permanently in eukitt and examined by 
microscopy. 
Isolation and purification of recombinant endonexin II 
Sf9 cells were seeded in 160 cm2 tissue culture flasks and infected with baculovirus Ac-
endol.4AE with a multiplicity of infection (M.O.I.) of 5. Four days post infection cells 
were harvested. After centrifugation, the cells were homogenized in buffer Η using a 
glass-glass Potter Elvehjem. Nuclei and unbroken cells were pelleted at 800xg. CaCl2 was 
added to the supernatant to a final concentration of 1 mM. After 1 hr on ice, a 
phospholipid-endonexin Π complex was pelleted at lOO.OOOxg (20 min, 4°C). The pellet 
was washed once with buffer H, containing 1 mM CaCl2. The final pellet was suspended 
vigorously in buffer Η containing 2 mM EGTA. This suspension was left to stand for 30 
min and centrifugea at lOO.OOOxg. The supernatant contains pure endonexin Π as 
demonstrated by SDS-PAGE. However, in the first lOO.OOOxg centrifugation step, large 
amounts of endonexin Π are not co-pelleted with Ca++ and phospholipids. The super­
natant from this step was mixed with the phospholipid pellet from which endonexin II had 
been released in the previous EGTA centrifugation step. This suspension was sup­
plemented with Ca++ and left to stand on ice for 1 hr to enable new complexes to be 
formed. After centrifugation, endonexin Π was again released by EGTA treatment. After 
repeating this procedure three times, most of the endonexin Π is precipitated and the yield 
is maximal. 
Finally, EGTA supematants containing the recombinant protein were pooled and stored 
frozen. 
Radio-labeling of proteins 
5 μ% of recombinant endonexin Π were labeled with Na125I (Amersham, Buckinghamshire, 
UK) using Iodogen (l,3,4,6-tetrachloro-3a-6a-diphenylglycoluril, Pierce, Rockford, IL 
USA) as a catalyst according to the manufacturen prescription. 
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Binding of recombinant endonexin II to HBsAg 
To test the functional activity of the recombinant protein, binding studies were carried out 
as described in chapter 3. In short, equimolar amounts of major or large HBsAg or BSA 
as a control protein were coated on high binding capacity 96 wells micro-titre dishes 
(Greiner, Germany). After blocking aspecific binding sites with 3% gelatine in phosphate 
buffered saline (PBS, 2 hrs at room temperature), the wells were washed twice with 
PBS/0.05% Tween-20 and once with PBS. 100,000 cpm of iodinated recombinant endo-
nexin II in PBS supplemented with 2 mM CaCl2 and 2 mM MgCl2 was added to the 
wells. After a two hour incubation at room temperature, the dishes were washed exten-
sively with PBS/Ca++/Mg*+ until no more radioactivity was released. Bound protein was 
released by adding PAGE sample buffer to the wells. Released proteins were denatured at 
100°C for 5 min and subjected to SDS-PAGE and autoradiography. 
In parallel experiments, after the two hrs incubation period, the nonreversible cross-
linking agent disuccimidylsuberate (DSS, Pierce) in dimethylsulfoxide (DMSO) was added 
in a final concentration of 1 mM. After the crosslinking reaction (30 min at 4°C), 100 
mM glycine was added to stop the reaction. Formed complexes were released in SDS-
PAGE sample buffer and subjected to SDS-PAGE and autoradiography. 
RESULTS 
Isolation and cloning of endonexin II encoding cDNA 
In order to isolate the cDNA, encoding human endonexin II, a human liver cDNA library 
in phage Lambda ZAP was screened with specific 32P-labeled synthetic oligonucleotides. 
Five independent clones were picked from this library and plaque purified, and their 
identity was reconfirmed by positive hybridization of the purified plaques to a second 
endonexin II-specific oligomer (results not shown). The inserts were rescued by helper 
phage R408 to yield the plasmid pBluescript with the cDNA fragment in the EcoRl 
restriction site of the multiple cloning site. 
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All five clones were identical and contained full length cDNA inserts of approximately 
1470 base pairs as was determined by DNA sequencing (results not shown). The cDNA 
sequences of these clones contained intact start and stop codons and were identical to the 
published sequence of human placental endonexin Π, including 5' and 3' non-coding 
regions (7). One of these cDNA's was cloned in the baculovirus transfer vector pVL941 
to yield the pVLendo vectors as described in materials and methods. 
The endonexin Π cDNA contains a ISO bp non-coding region at its 5'-terminus. Because 
a large distance between promoter and initiation codon might have a negative effect on 
the efficiency of the promoter, we removed most of this region by digesting the cDNA at 
a unique Avail site, 34 base pairs upstream from the initiation codon. The resulting 
Avall-EcoRl and the EcoRl-EcoRl fragments were cloned in pVL941 to yield pVLendo-
1.4AE, pVLendo-1.5EE and pVLendo-1.4EA (non-coding orientation of А аП-EcoRl 
fragment, functioning as a control). 
The result of this procedure is the replacement of part of the polyhedron gene in pVL941 
by endonexin Π cDNA, which is thus placed under the control of the very efficient 
polyhedrin promoter. The original polyhedrin ATG start codon in pVL941 has been 
changed by site directed mutagenesis to a non-sense ATT codon (12). When the pVL­
endo transfervectors are cotransfected with wild type AcNPV DNA in Sf9 cells, 
homologous recombination occurs with a frequency of 1-5% at a site near the polyhedrin 
gene, resulting in the integration of the endonexin Π cDNA in the AcNPV genome. In 
this process, the wild-type polyhedrin initiation codon is replaced by the mutated ATT 
codon from pVL941. So, for translation of recombinant RNA the foreign start codon is 
used. The recombinant protein product is thus not produced as a fusion protein which 
means that it will have the best possible resemblence to the native protein. 
After cotransfection of the transfervectors pVLendo-l.SEE, pVLendo-1.4AE and 
pVLendo-1.4EA with wild type AcNPV DNA, recombinant vims was purified from wild 
type AcNPV to yield respectively Acendo-l.SEE, Acendo-1.4AE and Acendo-1.4EA. The 
purification scheme for virus Acendo-1.4AE is presented in figure 2. After three rounds 
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of purification, cells were free of wild type baculovirus, as shown by negative 
hybridization of dot blots with the 535 bp poly-hedrin fragment of wild type virus. The 
titer of recombinant virus in the supernatant, as determined by infection of Sf9 cells in 
96-wells culture dishes with serial dilutions of virus stock, was approximately 107/ml. 
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Figure 5.2 Purification of recom­
binant baculovirus AcendolAAE 
by dot blotting. After cotransfec-
ting pVLendo-lAAE with AcNPV 
DNA, Sf9 cells were cultured for 
5 days and a l(f dilution of cul­
ture medium was used to infect 
new Sf9 cells in 96 wells culture 
dishes. After 4 days, cells were 
lysed and dot blots were prepared 
and hybridized as described in 
Materials and Methods (dotblot 
I). This procedure was repeated 
twice using a Iff dilution of 
medium from respectively well 
12f, giving rise to dotblot 2, well 
3g, giving rise to dotblot 3 and 
well 8a, giving rise to dotblot 4. 
In the last Infection, a serial 
dilution was used to determine the 
virus titer. Medium from well 12h 
was amplified in 75 cm2 culture 
flasks. Arrows indicate the 
respective wells that were used 
for further purifications. 
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SDS-PAGE and western blotting of recombinant Sf9 celh 
To test infected cells for recombinant protein production, whole cell lysates were 
prepared from 50,000 cells and subjected to SDS-PAGE and Western blotting. Figure 5.3 
shows a Coomassie Brilliant Blue stained Polyacrylamide gel (fig. 5.3A) and the cor­
responding Western blot of cells (fig. 5.3B, infected with Acendo-1.5EE (lanes 1), Ac-en-
dol.4AE (lanes 2) and Ac-endol.4EA (lanes 3). Using laser densitometry on the Western 
blots, we estimated that at least 8 mg of recombinant protein is produced by 5x10* Sf9 
cells, infected with Ac-endol.4AE. As expected, the removal of the 135 bp at the 5'-
noncoding region led to a significant increase of endonexin II expression (compare lanes 1 
and 2). 
Iso-electric focusing and SDS-PAGE of recombinant endonexin II, revealed that the iso­
electric point and molecular weight are identical to that of native endonexin II (figure 4A 
and 4B, compare lanes 1 and 2). 
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Figure 5.3 SDS-PAGE and Western blotting of 
recombinant endonexin II. 3 days after infection 
with Acendo-l.SEE (lanes 1), Acendo-IAAE 
(lanes 2) or Acendo-IAEA (lanes 3), Sf9 cells 
were lysed in SDS-PAGE sample buffer. Panel A 
represents a Coommassie Brilliant Blue stained 
10% Polyacrylamide gel, panel В the con­
comitant Western blot, stained with rabbit-anti 
human endonexin II. The arrow indicates the 
position of 34 Ю protein. 
A 
M 1 2 M 
В 
1 2 M 
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Figure 5.4 Comparison of recombinant and native 
endonexin II concerning molecular weight and iso­
electric point. Panel A: Phast System IEF gel pH 4-
6.8. Lane M: pH markers pi 9.3. 8.65, 8.45, 8.15, 
7.35, 6.85, 6.55, 5.85, 5.20, 4.55, 3.5, lane 1: 
recombinant endonexin II; lane 2: native endonexin 
II. Both gels were stained with Coomassie Brilliant 
Blue following the manufacturers instructions. Panel 
B: Phast System SDS-PAGE gradient gel (8-25% 
Polyacrylamide). Lane M: Mw markers 92, 68, 45, 
29, 21 and 14 kD; lane 1: purified recombinant 
endonexin II; lane 2: purified native endonexin II. 
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lmmunocytochemical studies on infected Sf9 cells 
Figure 5.5 Immunoperoxidase staining of infected recombinant Sf9 cells. Sf9 cells were infected 
with Ac-endol.4AE, fixed and stained with anti-endonexin II as stated in Materials and Methods. 
Panel A-E: 1-5 days post infection, panel F: wild-type AcNPV infected Sf9 cells. The arrow in 
panel E shows leakage of recombinant protein, the arrow in panel F points at polyhedrin 
accumulations. 
I l l 
Endonexin II is a membrane associated protein. We performed immunocytochemical 
studies to investigate the localization of the recombinant protein in infected Sf9 cells. The 
results are shown in figure 5. From 1 to 3 days post infection (p.i.) gradually more cells 
are producing membrane bound endonexin Π (panels A through C). 4 days p.i., the 
recombinant product starts to accumulate in the cytoplasm in high amounts (panel D). At 
S days p.i. most of the cells detach from the monolayer and burst (panel Б, arrow 
indicates leakage of recombinant protein). 
Sf9 cells, infected with wild-type AcNPV, do not react with our antiserum (panel F, note 
the high amounts of polyhedrin produced (arrow)). As expected there was also no 
reaction on Sf9 cells, infected with Ac-endol.4EA (results not shown). Rabbit pre­
immune serum did not react with Ac-endol.4AE infected cells (results not shown). 
Isolation and purification of recombinant human endonexin II 
From SDS-PAGE and immunoperoxidase staining of infected cells, it is obvious that at 
day 4 p.i. more than 90% of cells are infected and the production of recombinant protein 
is optimal. Although there is some loss of recombinant endonexin II to the culture 
medium (due to lysed cells), we choose to use cells at this stage of infection to isolate 
recombinant protein. 
To purify the recombinant protein, a modified version for the purification of endonexin II 
from human placenta as previously published was used (3). This procedure is based on 
the phospholipid binding properties of endonexin Π in the presence of Ca2*. After 
pelleting a phospholipid/Ca2+/endonexin II complex, endonexin II is released from this 
complex when incubated with EGTA. This procedure is also applicable to recombinant 
Sf9 cells, as shown on the western blot in figure 6. Lane 1 contains 2 μg of total 
homogenate protein of Sf9 cells, infected with Acendo-1.4AE. After removal of nuclei 
and precipitation with Ca2+, the pellet contains endonexin Π (lane 2), which is released in 
the supernatant after incubation with EGTA (lane 4). However, lane 3 shows that 
considerable amounts of recombinant endonexin Π can not be precipitated with Ca2* 
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(considering that the volume of the supernatant was approximately 20 times the volume of 
the resuspended pellet). This is probably due to the large excess of recombinant protein as 
compared to the amount of phospholipids present. To purify this non-precipitable protein, 
the Ca2+ precipitation was repeated twice using the phospholipid pellet from the first 
precipitation step after it had been cleared from endonexin Π with EGTA (lane 5 and 6 
respectively). The pooled EGTA supernatants contained only one protein band on SDS 
and IEF gels (figure 4, lanes 2). 
Figure 5.6 Western blot, stained with rabbit anti-human endonexin II, illustrating isolation and 
purification of recombinant endonexin II. Recombinant endonexin II was isolated from Ac-
endolAAE infected Sf9 cells using its property as a Ca2*-dependent phospholipid binding protein. 
Every lane contains 2 μg of protein. Lane 1 shows a total homogenate, lane 2 the pellet after 
Ca2*-precipitation as described in Materials and Methods. Lane 3 contains proteins, present in the 
supernatant after Ca2* precipitation. After washing the phospholipid pellet with buffer Η 
containing EGTA, endonexin II is released in the supernatant (lane 4). The washed pellet is 
however capable of renewed binding to endonexin II, as is shown in lane 5 (after second round of 
binding and EGTA treatment) and lane 6 (after third round of binding and EGTA treatment). 
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Recombinant endonexin II binds very effieciently to HBsAg 
В 1 2 
Figure 5.7 Functional activity of 
recombinant endonexin II. 
a) Ca1*- and Mg1*-dependent 
binding of recombinant endonexin 
II to HBsAg. Radio-labeled re­
combinant endonexin II was 
added to solid phase coated 
HBsAg as described in Materials 
and Methods. After incubation, 
bound endonexin II was released, 
subjected to SDS-PAGE and auto­
radiography. Binding assays of 
endonexin II on major HBsAg 
were performed in PBS (lane 1), 
PBS with Ca** (lane 2), PBS 
with Mg** (lane 3) and PBS with 
both Ca** and Mg** (lane 4). 
b) Binding of recombinant en­
donexin II to solid phase coated 
major HBsAg (lanes 1), large 
HBsAg (lanes 2), preSl (lanes 3) 
and BSA (lanes 4) (all ex­
periments in duplicate). 
c) DSS cross-linking of endonexin 
II bound to major HBsAg. Lane 
1: no crosslinker added; lanes 2 
and 3: DSS added (duplicate 
experiment). 
Arrows represent molecular 
weight markers: Downward 92 
kD, 68 kD, 45 kD, 29 Ю and 21 
kD. 
A 1 2 3 4 
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Purified recombinant endonexin II was labeled with 1 2 5I using the Iodogen method to a 
specific activity of 4 χ IO7 cpm//xg protein. This radiolabeled preparation, consisting of 
only one protein band in SDS gels, was used in binding assays on HBsAg as described in 
Materials and Methods. Figure 5.7a shows the result of such a binding experiment on 
major HBsAg. It is clear from this autoradiograph that the binding of recombinant 
endonexin Π to HBsAg is strictly CaI+- and Mg2+- dependent. When the incubation 
mixture contains no Ca2+, there is no binding at all (lanes 1 and 3). Addition of Ca2* and 
Mg2+ drastically increases the amount of binding of endonexin II. Addition of only Ca2* 
leads to a moderate binding. This same effect was observed when purified native 
endonexin Π was used in a binding study (results not shown). 
Figure 5.7b shows the results of a binding experiment in which the binding capacity of 
major HBsAg, large HBsAg and synthetic preSl was investigated. As is the case for 
native human endonexin Π, large HBsAg also is capable of efficient binding to endonexin 
Π (lanes 2, duplicate experiments). There is a negligible binding to synthetic preSl 
peptide (lanes 3) and no binding at all to BS A (lanes 4). Figure 7c shows the complexes 
that are formed when radiolabeled endonexin Π is cross-linked to major HBsAg (lane 2). 
A protein complex with an apparent molecular weight of 85 kilodaltons is formed. This 
protein complex might be the result of one endonexin Π molecule (34 kD) and two 
HBsAg molecules (2x26 kD) or two molecules of endonexin Π with one molecule of 
HBsAg. 
DISCUSSION 
In previous work we have demonstrated that human endonexin II is involved in the Ca+ +-
dependent binding of HBsAg to the human liver cell (5,10,11). Endonexin II is a member 
of the family of annexins, a group of highly conserved proteins with Ca2+-dependent 
phospholipid binding properties. The function of these proteins is not clear. It has been 
suggested that they may be involved in endocytosis and exocytosis by promoting 
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membrane fusion (8). As described elsewhere (S), a rabbit antiserum was raised against 
highly purified human liver endonexin II. After several boosts, anti-idiotypic antibodies, 
reacting with HBsAg, appeared. Since the endonexin Π preparation, used to immunize 
this rabbit, was proved to be not contaminated with HBsAg, the appearance of anti-
idiotypic anti-HBsAg antibodies can only be explained by a ligand-receptor relationship of 
endonexin Π and HBsAg. 
Interestingly, this rabbit antiserum did not react with endonexin II, isolated from rat liver, 
despite a 92% amino acid sequence homology between human and rat endonexin Π (4). 
Because endonexin Π from different species differ mostly in the N-terminal regions, this 
lead to the hypothesis that these antibodies might be directed to the non-conserved N-
terminal region of endonexin Π, which is the region that is exposed and therefore might 
be considered as the part of endonexin Π, having HBsAg-receptor activity. 
Despite the large amount of evidence that is available now that endonexin II serves as a 
binding protein for HBsAg, its biological role is not clear yet, e.g. the question remains 
to be answered whether endonexin Π also serves a role as a receptor for the complete 
hepatitis В virus particle, thus permitting viral penetration into the liver cell, the initial 
step of infection. Because of its HBsAg binding properties, endonexin Π can be con­
sidered to be a very serious candidate as a HBV receptor. Experiments that have to be 
done to definitely prove the biological role of endonexin II in HBV infection, and to 
understand the whole cascade of virus entry into the liver cell would involve for instance: 
- In vivo studies: challenging HBV infected animals (chimpanzees) with endonexin Π, 
synthetic endonexin Π peptides, containing the HBsAg binding site, or antibodies 
against the binding sites on HBsAg for endonexin II or vice versa. Inhibition of 
infection by endonexin Π (analogues) would indicate a biological function for this 
protein as HBV receptor. 
- In vitro studies: Endonexin II cDNA transfection experiments with HBV-permissive, 
but non-infectable cell lines. When these cell lines produce HBsAg-binding endonexin 
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II on their cell surfaces, they should be able to get infected with the virus. 
If it is indeed possible to prove the HBV-receptor function of endonexin Π, then this 
research will have a lot of potential implications for vaccine development and even for 
therapy of chronic hepatitis В patients. When it is possible to block the interaction 
between virus and liver cell, the continuing re-infection of the liver in these patients 
might be stopped, leading to recovery. 
To conduct research to the mechanism of virus entry, large amounts of functionally active 
receptor protein are required. To achieve this goal, we chose to clone the endonexin Π 
cDNA in the well defined baculovirus expression system. This system is nowadays widely 
used for the high-yield production of all kinds of eucaryotic proteins (3,9,13). 
The recombinant protein that is produced in this system has the same molecular weight 
and iso-electric point as the native protein. Moreover, it behaves identical as the native 
protein in regard to HBsAg binding and phospholipid binding, as it can be isolated using 
a protocol for the isolation of native endonexin Π, based on Ca2+-dependent phospholipid 
binding properties. When cross-linking studies are performed with major HBsAg and 
endonexin Π, complexes are found with molecular weights that indicate the presence of 
two binding sites on endonexin II for HBsAg, or two binding sites on HBsAg for 
endonexin Π. 
The availability of large amounts of recombinant endonexin Π, functionally active in 
regard to HBsAg binding, may therefore be of considerable importance in future hepatitis 
В research. 
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SUMMARY AND CONCLUSIONS 
CHAPTER 6: SUMMARY 
SUMMARY 
in chapter 1 a literature overview is presented regarding hepatitis B. The following 
subjects are paid attention to: 
- the hepatitis В virus structure 
- the molecular biology of the virus; the viral genome and its products are discussed in 
detail 
- some epidemiological and clinical aspects of hepatitis В infection, correlation with the 
hepatocellular carcinoma 
- a review is presented in section 1.10 regarding the possible causes for the distinct 
tissue- and species tropism of the hepatitis В virus. These causes are proposed to be 
twofold: 
1) the presence of a species-specific receptor molecule on permissive cells and 
2) the presence of tissue-specific factors that bind to the viral genome and that appear 
to be obligatory for viral replication 
In chapter 2 evidences are given for the existence of receptor molecules for the small 
hepatitis В surface antigen on the surface of human hepatocytes, although it has been 
suggested in the literature that the Dane particle binds via an amino acid sequence in the 
preSl region to receptor molecules on the hepatocyte surface, with a possible additional 
binding site on the preS2 region (this binding is mediated via polymerized human serum 
albumin). 
In our experiments using intact isolated human hepatocytes, a specific binding of 
recombinant small HBsAg to intact human hepatocytes and various other human cell 
types, but not to rat hepatocytes is demonstrated. Large HBsAg is not able to bind to 
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intact hepatocytes. In contrast, large HBsAg binds specifically to isolated human but not 
rat liver membrane preparations. We conclude that human hepatocytes present binding 
molecules on their surface for the small HBsAg. We also propose that species-specific 
intracellular receptor molecules exist with an affinity for large HBsAg, involving in part 
the preSl sequence. The presence of such intracellular receptors might be important for 
viral secretion from the cell. 
In chapter 3 we describe the presence of a HBsAg-binding hepatic membrane protein with 
a molecular weight of 34 kD. This p34 is present in human liver but not in rat liver. This 
protein binds with comparable efficiency to small and middle HBsAg and twice as much 
to the large HBsAg. In contrast, p34 does not bind to other proteins such as asialofetuin, 
Ig A or bovine serum albumin, suggesting that these proteins or their receptors are not 
involved in the specific binding between HBsAg and p34 as suggested in the literature. 
In chapter 4 we describe experiments in which the p34 is identified. By means of 
preparative SDS-polyacrylamide gel electrophoresis we have isolated large amounts of 
liver membrane proteins with molecular weights ranging from 32 to 36 kD. This partially 
purified protein fraction was subjected to two dimensional electrophoresis and the p34 
binding protein spot was identified by using a tracer amount of radiolabelled p34 from a 
binding experiment. Corresponding protein spots were collected and subjected to amino 
acid sequence analysis. Computer based analysis revealed that this p34 is endonexin Π, a 
Ca2+-dependent phospholipid binding protein. This protein was subsequently highly 
purified from human liver tissue, using a previously published protocol, and specific 
antibodies were raised in a rabbit. The identity of endonexin II as a HBsAg binding 
protein is confirmed by binding studies as described in chapter 3. Additional important 
evidence for the ligand-receptor relationship of HBsAg and endonexin Π was obtained by 
the finding of anti-idiotypic antibodies in rabbits, immunized with endonexin Π. These 
antibodies are spontaneously reacting to HBsAg. 
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Chapter 5 involves the cloning and high level expression of endonexin Π in the 
baculovims system. Based on the already published cDNA sequence of human placental 
endonexin Π, oligonucleotides were synthesized in order to screen a liver cDNA library. 
Full length cDNA from reactive clones were completely sequenced and were identical to 
the cDNA sequence of placental endonexin II. Endonexin Π cDNA was cloned in the 
baculovims expression system. The recombinant protein was produced in high amounts 
and was easy to purify, according to previously published protocols (used to isolate the 
native protein from human tissues). This recombinant protein has identical binding 
properties as the native protein. We propose that this protein might play an important role 
in future hepatitis В research. 
To investigate whether this protein has a biological function as a HBV receptor, further 
experiments to demonstrate that this protein (or endonexin Π derived peptides or 
antibodies against binding sites on endonexin Π or HBsAg) is able to block HBV infection 
in permissive cell lines or animals are necessary. If these experiments are successful, then 
this protein might become of considerable importance in HBV vaccine development and 
even treatment of chronic hepatitis B. 
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SAMENVATTING 
In hoofdstuk 1 wordt een literatuuroverzicht gegeven betreffende hepatitis B. Aan de 
volgende punten wordt aandacht besteed: 
- de structuur van het hepatitis В virus 
- de molekulaire biologie van het virus: het virale genoom en de transcriptie /trans-
latieprodukten worden in detail behandeld 
- bepaalde epidemiologische en klinische aspekten van infectie met het hepatitis В virus 
en de correlatie met levercel carcinomen 
- in hoofdstuk 1.10 wordt een overzicht gegeven betreffende de mogelijke oorzaken 
voor de gastheer- en weefselspecificiteit van de infectie met het hepatitis В virus. 
Deze factoren kunnen in twee richtingen gezocht worden: 
1) de aanwezigheid van een gastheerspecifiek receptor molekuul in permissieve cellen 
2) de aanwezigheid van weefselspecifieke factoren die binden aan het virus DNA en 
die noodzakelijk blijken voor virus replikatie. 
m hoofdstuk 2 worden bewijzen geleverd voor het bestaan van specifieke eiwit molekulen 
op humane levercellen die met het small HBsAg kunnen binden, ondanks dat in de 
literatuur de opvatting heerst dat het virus partikel aan de levercel bindt via preSl 
sequenties in het large HBsAg, en een mogelijke additionele bindingsplaats in de preS2 
regio (deze binding wordt gemedieerd door gepolymeriseerd humaan serum albumine). 
Door middel van bindingsexperimenten, uitgevoerd met intacte geïsoleerde levercellen en 
de verschillende recombinant HBsAg's hebben wij aangetoond dat small en middle 
HBsAg aan deze cellen (en andere humane celtypes) binden, maar niet aan rattelever-
cellen. Large HBsAg laat deze binding niet zien, maar bindt wel aan geïsoleerde 
levercelmembranen, een binding waarbij gedeeltelijk ook het preSl betrokken is hetgeen 
in overeenstemming is met de literatuur. We concluderen dat humane levercellen bin-
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dingsplaatsen voor small en middle HBsAg op hun oppervlakte presenteren, die 
verantwoordelijk zouden kunnen zijn voor virus penetratie. We suggereren dat er ook 
soortspecifieke intracellulaire receptoren bestaan die een rol zouden kunnen spelen bij de 
secretie van virus partikels uit de cel. 
In hoofdstuk 3 beschrijven we de aanwezigheid van een HBsAg bindend levermembraan 
eiwit met een molekuulgewicht van 34 kilodalton. Dit p34 bevindt zich in humane lever 
maar niet in rattelever. Het bindt vergelijkbare hoeveelheden small en middle HBsAg, en 
twee maal zoveel large HBsAg. p34 bindt niet aan andere eiwitten zoals asialo-fetuine, 
IgA en runder serum albumine. Deze controles werden uitgevoerd omdat gesuggereerd is 
dat de IgA receptor of de asialoglycoprotein receptor als HBV receptor zou functioneren. 
In hoofdstuk 4 beschrijven we experimenten waarin we p34 identificeren. Middels 
preparatieve eiwitgel-elektroforese hebben we grote hoeveelheden levermembraaneiwit 
geïsoleerd met molekulair gewichten tussen 32 en 36 kD. Van dit onzuivere preparaat 
werden 2D gels gedraaid met als tracer radioactief gelabeld p34 uit een bindingsstudie. 
Corresponderende eiwitspots werden verzameld en gebruikt voor aminozuursequentie 
analyse. Door middel van computeranalyse konden we p34 identificeren als en-
donexine II, een Ca2+- en fosfolipid bindend eiwit dat aanzienlijke homologie heeft met 
endonexine Π van andere diersoorten (92% met rat). Dit eiwit hebben we gezuiverd 
volgens een gepubliceerd protocol. Vervolgens zijn specifieke antilichamen opgewekt in 
een konijn. De functie van endonexin II als HBsAg bindend eiwit is verder bevestigd door 
middel van bindingsstudies zoals beschreven in hoofdstuk 3 en door het feit dat in het 
geïmmuniseerde konijn anti-idiotype antilichamen gevormd zijn die reageren met HBsAg. 
Hoofdstuk 5 gaat over de klonering en expressie van endonexine Π in het baculovirus 
systeem. Met synthetische oligonucleotiden, gemaakt op basis van de uit de literatuur 
bekende endonexine Π cDNA sequentie (placentaal), is een compleet endonexine Π cDNA 
uit een lever cDNA bank geïsoleerd. De DNA sequentie van dit leverendonexine Π was 
identiek aan die van placenta endonexin II. Het cDNA is gedoneerd in het baculovirus 
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expressie systeem. Het recombinant eiwit werd in grote hoeveelheden aangemaakt in dit 
systeem en was eenvoudig te zuiveren met methoden, analoog aan die voor de isolatie van 
endonexin Π uit humane weefsels. Het eiwit heeft identieke bindingseigenschappen ten 
opzichte van HBsAg als het natieve eiwit. We suggereren dat dit eiwit een belangrijke 
plaats zou kunnen innemen in toekomstig hepatitis В onderzoek. 
De biologische betekenis van dit eiwit als HBV receptor zal onderzocht moeten worden 
door middel van experimenten waarin infectie in permissieve dieren of cellijnen geremd 
kan worden door toedienen van endonexine П, of afgeleide peptiden van endonexine II, of 
antilichamen tegen de bindingsplaats voor endonexin Π op HBsAg. Als dergelijke ex­
perimenten een positief resultaat opleveren, zouden endonexine Π-afgeleide agentia van 
belang kunnen worden bij HBV vaccin ontwikkeling en voor de behandeling van 
chronische hepatitis В patiënten. Als de bindingsplaatsen voor de levercel op het viruspar-
tikel afgeblokt kunnen worden, dan kan de voortdurende herinfectie van hepatocyten in 
chronische hepatitis В patiënten voorkomen worden. In combinatie met passieve im-
munisatie met immuunglobulines tegen HBsAg zou het virus compleet verwijderd kunnen 
worden. 
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LIST OF ABBREVIATIONS 
Ab2 
AcNPV 
ALT 
ASF 
ASGPR 
bp 
BSA 
CBB 
cccDNA 
cDNA 
CHAPS 
CNBr 
DHBV 
DMSO 
DNA 
DR1/DR2 
DSS 
E-II 
ELISA 
ER 
FBS 
FCS 
g 
GSHV 
HAV 
HBcAg 
HBeAg 
HBMC 
HBsAg 
HBV 
HBxAg 
HCC 
HCV 
HDV 
Hepadna 
HEV 
HHV 
HIV 
HNF-1 
HPLC 
anti-idiotypic antibody 
autographa californica nuclear 
polyhedrosis vims 
alanine transferase 
asialofetuin 
asialoglycoprotein receptor 
base pairs 
bovine serum albumin 
coomassie brilliant blue 
covalently closed circular DNA 
copy DNA 
3-[(3 cholamidopropyl) dimethyl-
ammonio]-1 -propane-sulfonate 
cyanogen bromide 
duck hepatitis В virus 
dimethylsulfoxide 
deoxyribonucleic acid 
direct repeats 1 and 2 
disuccinmidyl suberate 
endonexin II 
enzyme linked immunosorbent 
assay 
endoplasmic reticulum 
fetal bovine serum 
fetal calf serum 
gravity force 
ground squirrel hepatitis virus 
hepatitis A virus 
hepatitis В core antigen 
hepatitis В early antigen 
human blood mononuclear cells 
hepatitis В surface antigen 
hepatitis В virus 
hepatitis Β χ antigen 
hepatocellular carcinoma 
hepatitis С virus 
hepatitis δ virus 
hepatitis associated DNA virus 
hepatitis E virus 
heron hepatitis В virus 
human immunodeficiency virus 
hepatocyte nuclear factor 1 
high performance liquid 
chromatography 
IEF 
IFN 
IgA 
IL-1 
IL-6 
Kb 
Kd 
Ш 
мне 
Mw 
NANB 
ORF 
PAGE 
PBS 
pHSA 
PMSF 
RNA 
rpm 
RT 
SDS 
SF9 
SV^O 
TCA 
TMB 
TNF 
TSHV 
WEM 
WHV 
isoelectric focusing 
interferon 
immunoglubulin A 
interleukin 1 
interleukin 6 
kilobases 
dissociation constant 
kilodalton 
major histocompatibility complex 
molecular weight 
non-Α non-B 
open reading frame 
Polyacrylamide gel electrophoresis 
phosphate buffered saline 
polymerized human serum albumin 
phenylmethylsulfonylfluoride 
ribonucleic acid 
rotations per minute 
room temperature 
sodium dodecyl sulfate 
spodoptera frugiperda 
simian vims 40 
trichloro acetic acid 
tetramethylbenzidine 
tumor necrosis factor 
tree squirrel hepatitis virus 
Williams' essential medium 
woodchuck hepatitis virus 
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NAWOORD 
Zoals bij elk proefschrift het geval is, is ook bij het tot stand komen van dit proefschrift 
de bijdrage van een aantal mensen onontbeerlijk geweest. Enkelen daarvan wil ik met 
name noemen. 
Harrie Glansbeek heeft, eerst tijdens een stage in het kader van de studie biologie en 
vervolgens tijdens zijn vervangende dienstplicht, een grote rol gespeeld bij de opzet en 
uitvoering van de bindingsexperimenten die beschreven staan in hoofdstuk 2. 
Bert Siebers heeft mij in het kader van een extra stage behoorlijk wat werk uit handen 
genomen bij de kloneringen die beschreven zijn in hoofdstuk 5. 
Jan Jansen ben ik zeer dankbaar omdat hij mij onder onconventionele condities toch de 
(lab)ruimte heeft geboden om dit onderzoek af te maken. 
Als wij van de technische vaardigheden van een aantal mensen verstoken waren gebleven, 
zou dit proefschrift alleen de hoofdstukken 1 tot en met 3 hebben omvat. Vooral Lydie 
Meheus en Jos Raymackers van Innogenetics, Gent, België ben ik erkentelijk voor twee-
dimensionele eiwitgelelektroforese en aminozuur analyse. 
Louis, Toon, Jules en Ewald van de afdeling Hematologie die altijd zo vriendelijk waren 
om ons millicuries MP-dCTP te lenen en daar ongeveer de helft van terug te krijgen, en 
dan óók nog eens oligo's voor ons te synthetiseren. De DNA sequentie gel apparatuur van 
deze afdeling heeft mij ook veel profijt gebracht. 
Ton Kos wil ik bedanken voor het ter beschikking stellen van het baculovirus materiaal. 
En dan natuurlijk Wieke. We zijn zo'n vijf jaar met z*n tweeën behoorlijk op elkaar 
aangewezen geweest, hetgeen resulteerde in een samenwerking die volgens mij niet vaak 
voorkomt. Onze nachtbrakerijen waren altijd gezellig en leverden toch altijd vreselijk veel 
cellen op. Onderzoek doen kan dus ook gezellig zijn. 
En dan de rest van lab gastro. Ik heb met veel plezier zes jaar van mijn leven op dit lab 
doorgebracht, en niet in de laatste plaats door de niet van schelden verstoken kaartpauzes 
tussen de middag. Als ik iets zal missen is het dat wel. 
Yvonne Lawson wil ik bedanken voor het nakijken en corrigeren van het manuscript. 
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Mijn familie wil ik bedanken voor de nimmer aflatende interesse in mijn onderzoek. Als 
ik voor elke keer dat ik "De weet niet" antwoordde op de vraag wanneer ik nou eindelijk 
eens ging promoveren, een gulden gekregen had, zou ik nooit hebben hoeven klagen over 
mijn AIO salaris. 
Annette, aan jou kon ik altijd mijn frustraties kwijt als de experimenten weer eens mislukt 
waren (en zoals altijd in onderzoek was dat geen zeldzaamheid). Niets zo belangrijk dan 
iemand te hebben die een beetje weet waar je over praat en meeleeft. 
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STELLINGEN 
behorende bij het proefschrift: 
Identification and characterization of the putative 
hepatocellular receptor for the hepatitis В virus 
door: 
W.P.J. Leenders 
Nijmegen, 15 september 1993 
I De conclusie dat het hepatitis В virus large HBsAg verantwoordelijk is voor virus 
binding aan de levercel berust op de misvatting dat cellijnen, geïsoleerd uit 
levertumoren, dezelfde biologische eigenschappen hebben als normale hepatocyten 
Neurath et al. Cell 1986;46.429-436, dit proefschrift 
II Het niet kunnen aantonen van een binding van small HBsAg aan membraan-
preparaten van humane lever, gefixeerd op een solid phase, is een artefact dat 
waarschijnlijk veroorzaakt wordt door conformationele veranderingen van de bin-
dingsepitopen op de membranen ten gevolge van de fixatie 
Pontisso et al J Viral 1989,63 1981-1988, dit proefschrift 
III Als inhibitie van binding van een ligand aan zijn vermeende receptor optreedt 
onder invloed van antilichamen, worden er vaak conclusies getrokken omtrent 
bindingsepitopen terwijl geen rekening gehouden wordt met het 'aspecifieke' effect 
van stensche hindering 
Gerlich et al J of Hepatology 1993,17 (suppl 3).S10-14 
IV Dat HBsAg-bindend endonexine II voor zover onderzocht alleen voorkomt op 
cellen van hepatitis В virus permissieve species (niet gepubliceerde eigen waar­
neming), is een extra aanwijzing voor de HBV-receptor activiteit van dit eiwit 
V Dat endonexine II geen consensussequentie bevat voor een signaalpeptide, betekent 
met dat dit eiwit geen membraaneiwit is. Dit proefschrift. 
VI De aanhechting van hepatitis В virus aan de levercel is Ca2+ en Mg2 + afhankelijk. 
Dit proefschrift 
VII Moleculaire biologie en celbiologie wordt steeds meer onmisbaar in de opleiding 
voor geneeskundigen en specialisten 
Vili De aanwezigheid van hoge concentraties endonexine II in de placenta zou een 
verklaring kunnen zijn voor het niet voorkomen van transplacentaire infectie met 
hepatitis В virus. 
IX Het gescheiden inzamelen van afval zal leiden tot een extra opslagprobleem, en 
niet tot een oplossing van het afvalprobleem. 
X Opheffen van de anonimiteit van spermadonoren zal tot gevolg hebben dat sperma 
bijgeschreven kan worden op de lijst van schaarse donorweefsels. 
XI De ziektekosten ten gevolge van rugklachten door het niet vernieuwen/aanpassen 
van lab meubilair overstijgen zeer waarschijnlijk de kosten van een dergelijke 
operatie. 
XII Als de bloesemwemel van de kersenbomen op de heuvel langer zou duren dan één 
enkele dag, zouden we die niet zo innig minnen. Jamabe No Akahito 
XIII Pas nadat de kist is dichtgespijkerd, blijkt of de naam duurzaam is. Japanse 
wijsheid. 



